

[Home](#) [Browse Dictionaries](#) [More Dictionaries](#) [FAQ](#) [Privacy](#) [Contact](#) [Site Map](#)**ARE YOU HAPPY?**

click this banner to visit our sponsor

Search Results

Jump to: [Arts and Humanities](#), [Business](#), [Computer/Internet](#), [Medical](#), [Miscellaneous](#), [Religion](#), [Science](#), [Sports](#), [Technological](#), [General](#), [Slang](#)

Medical

1. Dictionary of Cancer Terms -includes definition (English), phonic pronunciation (164KB, indexed 22Jun2002)
Thanks to National Cancer Institute
1. [non-small cell lung cancer](#)
[To home page of this dictionary](#)(31KB)


Enter word:

Try these [additional links](#) for more translations, dictionaries, etc.

ARE YOU HAPPY?

click this banner to visit our sponsor

[Home](#) [Browse Dictionaries](#) [More Dictionaries](#) [FAQ](#) [Privacy](#) [Contact](#) [Site Map](#)



[dictionary](#)
 [site map](#)
 [search](#)

[home](#) [about NCI](#)

[cancer information](#)

[clinical trials](#)

[statistics](#)

[research programs](#)

[research funding](#)

Cancer.gov Dictionary

[A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#)

N

N-acetylcysteine

An antioxidant drug that may keep cancer cells from developing or reduce the risk of growth of existing cancer.

N-acetyldinaline

A substance that is being studied as an anticancer drug in the treatment of non-small cell lung cancer. Also called CI-994.

naloxone

A substance that is being studied as a treatment for constipation caused by narcotic medications. It belongs to the family of drugs called narcotic antagonists.

narcotic

An agent that causes insensibility or stupor; usually refers to opioids given to relieve pain.

nasal

By or having to do with the nose.

nasopharynx (NAY-zo-fair-inks)

The upper part of the throat behind the nose. An opening on each side of the nasopharynx leads into the ear.

National Cancer Institute

NCI. The National Cancer Institute, part of the National Institutes of Health of the United States Department of Health and Human Services, is the Federal Government's principal agency for cancer research. NCI conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer. Access the NCI Web site at <http://cancer.gov>.

National Institutes of Health

NIH. The National Institutes of Health, the focal point of biomedical research in the United States, conducts research in its own laboratories; supports the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helps

[DNA Microarrays Predict Lymphoma Patient Survival](#)

[New U.S. Cancer Trends Announced](#)

[Past Highlights](#)

[Kidney/Bladder Cancers Progress Review Group Report](#)

[news center](#)

[1-800-4-CANCER](#)
 Cancer Information Service

[help](#)
 • [Cancer.gov Help](#)
 • [FAQs](#)
 • [Index of NCI Sites](#)

[resources](#)
 • [Publications Locator](#)
 • [NCI Calendar of Scientific Meetings](#)
 • [Links to Other Web Sites](#)

[LiveHelp](#)
 cancer.gov

[Español Text](#)

nitrosour as (nye-TRO-so-yoo-REE-ahz)

A group of anticancer drugs that can cross the blood-brain barrier. Carmustine and lomustine are nitrosoureas.

NK cells

Natural killer cells. A type of white blood cell that contains granules with enzymes that can kill tumor cells or microbial cells. Also called large granular lymphocytes.

NMRI

Nuclear magnetic resonance imaging. A procedure in which a magnet linked to a computer is used to create detailed pictures of areas inside the body.

node-negative

Cancer that has not spread to the lymph nodes.

node-positive

Cancer that has spread to the lymph nodes.

nodular parenchyma

A small mass of tissue within a gland or organ that carries out the specialized functions of the gland or organ.

nodule (NOD-yool)

A growth or lump that may be cancerous or noncancerous.

nolatrexed

An anticancer drug that belongs to the family of drugs called thymidylate synthase inhibitors. Also called AG337.

non-Hodgkin's lymphoma

A group of cancers of the lymphoid system, including acute lymphoblastic leukemia, B-cell lymphoma, Burkitt's lymphoma, diffuse cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, mycosis fungoides, post-transplantation lymphoproliferative disorder, small non-cleaved cell lymphoma, and T-cell lymphoma.

non-small cell lung cancer

A group of lung cancers that includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

nonblinded

Describes a clinical trial or other experiment in which the researchers know what treatments are being given to each study subject or experimental group. If human subjects are involved, they know what treatments they are receiving.

nonconsecutive cases

A clinical study that includes some, but not all, of the eligible patients identified by the researchers during the study

Status: Path 1 of [Dialog Information Services via Modem]
Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 3106900061...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
***** HHHHHHHH SSSSSSS?
Status: Signing onto Dialog

ENTER PASSWORD:
***** HHHHHHHH SSSSSSS? *****
Welcome to DIALOG
Status: Connected

Dialog level 00.12.12D

Last logoff: 13feb01 07:35:47
Logon file405 13mar01 12:14:51
KWIC is set to 50.
HIGHLIGHT set on as '*'
PICKS is set ON as an alias for 5,55,159,143,358,340,344,348,351,352,447,72,73,154,1
55,349.
*** NEW Current Year Ranges Install ***

SYSTEM:HOME
Menu System II: D2 version 1.7.8 term=ASCII
*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2000 The Dialog Corporation plc All rights reserved.

/H = Help /L = Logoff /NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

?b picks

>>> 351 is unauthorized
>>> 352 is unauthorized
>>> 2 of the specified files are not available
13mar01 12:15:15 User243038 Session D56.1
\$0.00 0.230 DialUnits FileHomeBase
\$0.00 Estimated cost FileHomeBase
\$0.02 TYMNET
\$0.02 Estimated cost this search
\$0.02 Estimated total session cost 0.230 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 5:Biosis Previews(R) 1969-2001/Mar W1
(c) 2001 BIOSIS
File 55:Biosis Previews(R) 1993-2001/Mar W1

(c) 2001 BIOSIS
File 159:Cancerlit 1975-2000/Nov
(c) format only 2000 Dialog Corporation
***File 159: 12/2000, 01/2001, and 02/2001 updates are not yet available**
due to National Cancer Institute's delay in receiving the source data.
File 143:Biol. & Agric. Index 1983-2001/Feb
(c) 2001 The HW Wilson Co
File 358:Current BioTech Abs 1983-2000/Aug
(c) 2001 DECHHEMA
***File 358: Updates delayed. Please see HELP NEWS 358 for details.**
File 340:CLAIMS(R)/US PATENT 1950-01/Mar 06
(c) 2001 IFI/CLAIMS(R)
***File 340: Price changes as of 1/1/01. Please see HELP RATES 340.**
File 344:CHINESE PATENTS ABS APR 1985-2001/Feb
(c) 2001 EUROPEAN PATENT OFFICE
File 348:EUROPEAN PATENTS 1978-2001/Feb W04
(c) 2001 European Patent Office
File 447:IMSWorld Patents International 2001/Feb
(c) 2001 IMSWorld Publ. Ltd.
File 72:EMBASE 1993-2001/Mar W1
(c) 2001 Elsevier Science B.V.
***File 72: For information about Explode feature please**
see Help News72.
File 73:EMBASE 1974-2001/Mar W1
(c) 2001 Elsevier Science B.V.
***File 73: For information about Explode feature please**
see Help News73.
File 154:MEDLINE(R) 1993-2000/Dec W4
(c) format only 2000 Dialog Corporation
***File 154: Further to NLM notification, Medline updating is expected**
to resume in March 2001. For other NLM information see Help News154.
File 155:MEDLINE(R) 1966-2000/Dec W4
(c) format only 2000 Dialog Corporation
***File 155: Further to NLM notification, Medline updating is expected**
to resume in March 2001. For other NLM information see Help News155.
File 349:PCT Fulltext 1983-2001/UB=20010308, UT=20010222
(c) 2001 WIPO/MicroPat

Set	Items	Description
---	---	-----
?s metastatic cell?		
	S1	70 METASTATIC CELL?
?s s1 and sv40		
	70	S1
	57270	SV40
	S2	0 S1 AND SV40
?s s1 and immortaliz?		
	70	S1
	42060	IMMORTALIZ?
	S3	0 S1 AND IMMORTALIZ?
?s s1 and spread?		
	70	S1
	371913	SPREAD?
	S4	6 S1 AND SPREAD?
?rd		
>>>Duplicate detection is not supported for File 340.		
>>>Duplicate detection is not supported for File 344.		
>>>Duplicate detection is not supported for File 348.		
>>>Duplicate detection is not supported for File 447.		
>>>Duplicate detection is not supported for File 349.		
>>>Records from unsupported files will be retained in the RD set.		
...completed examining records		
	S5	3 RD (unique items)
?t s5/all		
>>>'ALL' not allowed as format type		
?t s5/5/all		

5/5/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12230244 BIOSIS NO.: 199900525093

Protein phosphatase-2A associates with the cytoskeleton to maintain cell *spreading* and reduced motility of nonmetastatic Lewis lung carcinoma cells: The loss of this regulatory control in metastatic cells.

AUTHOR: Jackson Jodi; Meisinger Jeremy; Patel Snehal; Lim Zenia C; Vellody Kishore; Metz Raymond; Young M Rita I(a)

AUTHOR ADDRESS: (a)Res. Serv., Hines V.A. Hosp., Hines, IL 60141**USA

JOURNAL: Invasion & Metastasis 17 (4):p199-209 July-Aug., 1997

ISSN: 0251-1789

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Metastatic Lewis lung carcinoma (LLC-LN7) variants have previously been shown to have reduced levels of protein phosphatase-2A (PP-2A) activity as compared to the nonmetastatic LLC-C8 cells. The present study showed that inhibition of PP2A in the nonmetastatic LLC-C8 cells caused a rapid change from a *spread* to a rounded morphology and increased their in vitro invasiveness through laminin. In contrast, the metastatic LLC-LN7 cells were rounded and invasive, which was not affected by inhibition of PP-2A. To determine whether these differences could be attributed to alterations in PP-2A association with the cytoskeleton, the extent of PP-2A colocalization with microtubules was tested. Immunostaining for tubulin showed prominent filamentous fibers in nonmetastatic LLC-C8 cells and small foci of PP-2A immunostaining along these microtubules. In contrast, the tubulin staining was diffuse throughout the metastatic LLC-LN7 cells and there was little evidence of association with PP-2A. Western blot analyses showed that this reduced level of PP-2A association with microtubules in metastatic LLC-LN7 cells was not due to differences in levels of the PP-2A subunits. Instead, it may be due to the reduced association of the subunits into the heterotrimeric form of the PP-2A holoenzyme. These studies show the importance of PP-2A in maintaining a *spread* morphology and in restricting invasiveness, and a loss of this regulatory control in metastatic cells. This loss of PP-2A regulatory control in metastatic cells may be due to a reduction in the trimeric form of the PP-2A holoenzyme.

DESCRIPTORS:

MAJOR CONCEPTS: Tumor Biology

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: LLC-C-8 cell line (Muridae)--cell *spreading*, *metastatic* cell *spreading* control loss, reduced nonmetastatic cell motility, mouse Lewis lung carcinoma cell line

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates

CHEMICALS & BIOCHEMICALS: protein phosphatase 2A--cytoskeleton association

CONCEPT CODES:

24006 Neoplasms and Neoplastic Agents-Biochemistry

02506 Cytology and Cytochemistry-Animal

10508 Biophysics-Membrane Phenomena

10808 Enzymes-Physiological Studies

15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial System

16006 Respiratory System-Pathology

24005 Neoplasms and Neoplastic Agents-Neoplastic Cell Lines

10064 Biochemical Studies-Proteins, Peptides and Amino Acids

12100 Movement (1971-)

32500 Tissue Culture, Apparatus, Methods and Media

BIOSYSTEMATIC CODES:

5/5/2 (Item 2 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2001 BIOSIS. All rts. reserv.

11938287 BIOSIS NO.: 199900184396

Differential gene expression associated with suppression of metastatic melanoma cell *spreading* and proliferation on adhesion-restrictive substrates.

AUTHOR: Rieber Manuel(a); Welch Danny R; Rieber Mary Strasberg(a)

AUTHOR ADDRESS: (a)IVIC, Tumor Cell Biol., Apartado 21827, Caracas 1020 A**
 Venezuela

JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 40p74 March, 1999

CONFERENCE/MEETING: 90th Annual Meeting of the American Association for Cancer Research Philadelphia, Pennsylvania, USA April 10-14, 1999

SPONSOR: American Association for Cancer Research

ISSN: 0197-016X

RECORD TYPE: Citation

LANGUAGE: English

DESCRIPTORS:

MAJOR CONCEPTS: Molecular Genetics (Biochemistry and Molecular Biophysics); Tumor Biology

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: C8161 cell line (Hominidae)--adhesion restrictive substrate culture, cell proliferation suppression, *metastatic cell spreading suppression*, *human melanoma cell line

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans; Mammals; Primates; Vertebrates

CHEMICALS & BIOCHEMICALS: KiSS-1 gene (Hominidae)--chromosome 6 localization, differential tumor cell expression, metastatic tumor cell *spreading* suppression association, tumor cell proliferation suppression association, gene therapy mechanism

MISCELLANEOUS TERMS: Meeting Abstract

CONCEPT CODES:

24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy

02508 Cytology and Cytochemistry-Human

03508 Genetics and Cytogenetics-Human

15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial System

24005 Neoplasms and Neoplastic Agents-Neoplastic Cell Lines

00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals

10508 Biophysics-Membrane Phenomena

12100 Movement (1971-)

12512 Pathology, General and Miscellaneous-Therapy (1971-)

25508 Developmental Biology-Embryology-Morphogenesis, General

32500 Tissue Culture, Apparatus, Methods and Media

BIOSYSTEMATIC CODES:

86215 Hominidae

5/5/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11780775 BIOSIS NO.: 199900026884

An in vivo/in vitro experimental model system for the study of human osteosarcoma: Canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice.

AUTHOR: Shoieb Ahmed M; Hahn Kevin A(a); Barnhill Mary A

AUTHOR ADDRESS: (a)Dep. Comparative Med., Coll. Vet. Med., Univ. Tenn., Knoxville, TN 37901-1071**USA

JOURNAL: In Vivo (Attiki) 12 (5):p463-472 Sept.-Oct., 1998

ISSN: 0258-851X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: In this report we describe the establishment, characterization, and research utility of a cell line derived from a dog having a spontaneously occurring osteosarcoma. Materials and Methods: Tumor samples were collected from a dog with a naturally occurring osteosarcoma and processed for light microscopy, electron microscopy, immunocytochemistry, immunohistochemistry, karyology, and cell culture. Established cells from passage 31 (COS31; canine Osteosarcoma cells from passage 31) were inoculated subcutaneously between the scapula and in the light abdominal side of athymic nude mice and evaluated similarly. Results: COS31 cells derived in cell culture and in nude mice had morphological and biochemical properties comparable in all respects to the original canine tumor specimen. Conclusions: The ability of COS31 cells to produce tumors in nude mice (i.e. a small animal model) typical of canine osteosarcoma (i.e. a large animal model) with a similar pathological and biological behavior (e.g. alkaline phosphatase and osteocalcin positive immunostaining, osteoid production, rapid growth, and wide *spread* metastases) demonstrates the potential utility of COS31 cells as a in vitro and in vivo model system in the development of new strategies in the treatment of human osteosarcoma.

DESCRIPTORS:

MAJOR CONCEPTS: Cell Biology; Skeletal System (Movement and Support); Tumor Biology
BIOSYSTEMATIC NAMES: Canidae--Carnivora, Mammalia, Vertebrata, Chordata, Animalia; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: mouse (Muridae)--nude; COS31 cell line (Canidae)--canine osteosarcoma cells
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Carnivores; Chordates ; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates
DISEASES: osteosarcoma--bone disease, in-vitro experimental model system, in-vivo experimental model system, neoplastic disease
MISCELLANEOUS TERMS: *metastatic cell properties*; osteoblastic cell properties

ALTERNATE INDEXING: Osteosarcoma (MeSH)

CONCEPT CODES:

24002 Neoplasms and Neoplastic Agents-General
02506 Cytology and Cytochemistry-Animal
18001 Bones, Joints, Fasciae, Connective and Adipose Tissue-General; Methods

BIOSYSTEMATIC CODES:

85765 Canidae
86375 Muridae

?s epithelial cell?

S6 25029 EPITHELIAL CELL?

?s s6 and s1

25029 S6

70 S1

S7 0 S6 AND S1

?s s1 and breast

70 S1

685957 BREAST

S8 14 S1 AND BREAST

?rd

>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 344.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 447.
>>>Duplicate detection is not supported for File 349.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S9 7 RD (unique items)

?t s9/5/all

9/5/1 (Item 1 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12289260 BIOSIS NO.: 200000047127

Phosphatidic acid enhances metastatic migration of *breast* cancer cells.

AUTHOR: Sliva Daniel(a); Mason Rebekah(a); English Denis(a)

AUTHOR ADDRESS: (a)Experimental Cell Research Program, The Methodist Research Institute, Indianapolis, IN**USA

JOURNAL: Blood 94 (10 SUPPL. 1 PART 2):p76b Nov. 15, 1999

CONFERENCE/MEETING: Forty-first Annual Meeting of the American Society of Hematology New Orleans, Louisiana, USA December 3-7, 1999

SPONSOR: The American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Citation

LANGUAGE: English

REGISTRY NUMBERS: 26993-30-6: SPHINGOSINE 1-PHOSPHATE

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Tumor Biology

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: MCF-7 cell line (Hominidae)--human *breast* cancer cell;

MDA-MB-231 cell line (Hominidae)--human *breast* cancer cell

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans; Mammals; Primates; Vertebrates

DISEASES: *breast* cancer--*metastatic cell migration*, neoplastic disease, reproductive system disease/female

CHEMICALS & BIOCHEMICALS: lipid phosphate messenger; phosphatidic acid; sphingosine 1-phosphate

MISCELLANEOUS TERMS: cellular process--receptor driven; metastatic potential; Meeting Abstract

ALTERNATE INDEXING: *Breast* Neoplasms (MeSH)

CONCEPT CODES:

24002 Neoplasms and Neoplastic Agents-General

02508 Cytology and Cytochemistry-Human

10060 Biochemical Studies-General

16501 Reproductive System-General; Methods

00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals

BIOSYSTEMATIC CODES:

86215 Hominidae

9/5/2 (Item 2 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11299024 BIOSIS NO.: 199800080356

Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function.

AUTHOR: Yu Qin; Toole Bryan P; Stamenkovic Ivan(a)

AUTHOR ADDRESS: (a)Mol. Pathol. Unit, MGH Cancer Cent., Mass. General Hosp., 149 13th St., Charlestown Navy Yard, B**USA

JOURNAL: Journal of Experimental Medicine 186 (12):p1985-1996 Dec. 15, 1997

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: To understand how the hyaluronan receptor CD44 regulates tumor metastasis, the murine mammary carcinoma TA3/St, which constitutively expresses cell surface CD44, was transfected with cDNAs encoding soluble isoforms of CD44 and the transfectants (TA3sCD44) were compared with parental cells (transfected with expression vector only) for growth in

vivo and in vitro. Local release of soluble CD44 by the transfectants inhibited the ability of endogenous cell surface CD44 to bind and internalize hyaluronan and to mediate TA3 cell invasion of hyaluronan-producing cell monolayers. Mice intravenously injected with parental TA3/St cells developed massive pulmonary metastases within 21-28 d, whereas animals injected with TA3sCD44 cells developed few or no tumors. Tracing of labeled parental and transfectant tumor cells revealed that both cell types initially adhered to pulmonary endothelium and penetrated the interstitial stroma. However, although parental cells were dividing and forming clusters within lung tissue 48 h following injection, >80% of TA3sCD44 cells underwent apoptosis. Although sCD44 transfectants displayed a marked reduction in their ability to internalize and degrade hyaluronan, they elicited abundant local hyaluronan production within invaded lung tissue, comparable to that induced by parental cells. These observations provide direct evidence that cell surface CD44 function promotes tumor cell survival in invaded tissue and that its suppression can induce apoptosis of the invading tumor cells, possibly as a result of impairing their ability to penetrate the host tissue hyaluronan barrier.

REGISTRY NUMBERS: 9004-61-9: HYALURONAN

DESCRIPTORS:

MAJOR CONCEPTS: Reproductive System (Reproduction); Tumor Biology

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: mouse (Muridae)

ORGANISMS: PARTS ETC: mammary carcinoma cells--apoptosis, reproductive system, *metastatic cells*

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates

DISEASES: *breast* cancer--neoplastic disease, reproductive system disease/female

CHEMICALS & BIOCHEMICALS: hyaluronan receptor; CD44--expression

MISCELLANEOUS TERMS: extracellular matrix

CONCEPT CODES:

24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects

02506 Cytology and Cytochemistry-Animal

10506 Biophysics-Molecular Properties and Macromolecules

10508 Biophysics-Membrane Phenomena

12510 Pathology, General and Miscellaneous-Necrosis (1971-)

16506 Reproductive System-Pathology

10064 Biochemical Studies-Proteins, Peptides and Amino Acids

BIOSYSTEMATIC CODES:

86375 Muridae

9/5/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11280948 BIOSIS NO.: 199800062280

Use of magnetic activated cell sorting for detection of minimal residual tumor cells in bone marrow of patients with *breast* cancer.

AUTHOR: Hempel D(a); Mueller P; Oruzio D; Ehnle S; Finkel M; Schlimok G

AUTHOR ADDRESS: (a)Central Hosp. Augsburg, II. Med. Klinik, Stenglinstr. 2, 86156 Augsburg**Germany

JOURNAL: Blood 90 (10 SUPPL. 1 PART 2):p380B Nov. 15, 1997

CONFERENCE/MEETING: Thirty-ninth Annual Meeting of the American Society of Hematology San Diego, California, USA December 5-9, 1997

SPONSOR: The American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Citation

LANGUAGE: English

DESCRIPTORS:

MAJOR CONCEPTS: Blood and Lymphatics (Transport and Circulation); Immune System (Chemical Coordination and Homeostasis); Reproductive System

(Reproduction); Tumor Biology
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: human (Hominidae)--patient
ORGANISMS: PARTS ETC: bone marrow--blood and lymphatics, *metastatic cells*, immune system; MNC (mononuclear cells)--blood and lymphatics, immune system
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans; Mammals; Primates; Vertebrates
DISEASES: *breast* cancer--neoplastic disease, reproductive system disease/female; minimal residual disease--neoplastic disease
CHEMICALS & BIOCHEMICALS: A45B-B3--monoclonal antibody fragment; HEA--monoclonal antibody
METHODS & EQUIPMENT: immunocytochemistry--detection method, sensitivity; magnetic activated cell sorting--detection method, sensitivity
MISCELLANEOUS TERMS: Meeting Abstract

CONCEPT CODES:

24002 Neoplasms and Neoplastic Agents-General
02508 Cytology and Cytochemistry-Human
10060 Biochemical Studies-General
15001 Blood, Blood-Forming Organs and Body Fluids-General; Methods
16501 Reproductive System-General; Methods
34502 Immunology and Immunochemistry-General; Methods
00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annals

BIOSYSTEMATIC CODES:

86215 Hominidae

9/5/4 (Item 4 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

10612768 BIOSIS NO.: 199699233913
Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in *breast* cancer.
AUTHOR: Lehrer S(a); Terk M; Piccoli S P; Song H K; Lavagnini P; Luderer A A
AUTHOR ADDRESS: (a)Radiation Oncol., Box 1236, Mount Sinai Med. Cent., New York, NY 10029**USA
JOURNAL: British Journal of Cancer 74 (6):p871-873 1996
ISSN: 0007-0920
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Among women with node-negative *breast* cancer and small turnouts, it is important to identify those with turnouts that will recur, so that they may receive adjuvant therapy, while sparing those with turnouts that will not recur the hazards of adjuvant treatment. A reverse transcriptase-polymerase chain reaction (RT-PCR) for prostate-specific antigen (PSA) may be used to identify circulating metastatic cells in patients with prostate cancer. Approximately 30% of *breast* cancer cells also produce PSA. Therefore, we tested the PSA RT-PCR assay on blood specimens from women with *breast* cancer. We evaluated 78 women at Mount Sinai Medical Center with histologically confirmed *breast* cancer. Venous blood (5 CM-3) from the women was collected in ethylene diaminetetraacetic acid (EDTA)-treated collection tubes and approximately 400 ng of RNA from each sample was subjected to an RT-PCR. We were able to detect the amplified PSA fragment in 18 of 78 women with *breast* cancer; 7 of the 18 women with the PSA fragment had localized, small, node-negative tumours, both oestrogen receptor (ER) positive and ER negative. We could not detect the amplified PSA fragment in 20 normal women and 22 normal men. We conclude that PSA RT-PCR may be a useful method for determining the presence of circulating metastatic cells in some women with node-negative *breast* cancer, and therefore the potential for these women to develop recurrent disease and thus benefit

from adjuvant therapy.

DESCRIPTORS:

MAJOR CONCEPTS: Immune System (Chemical Coordination and Homeostasis);
Oncology (Human Medicine, Medical Sciences); Reproductive System
(Reproduction)

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,
Animalia

ORGANISMS: human (Hominidae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans;
mammals; primates; vertebrates

MISCELLANEOUS TERMS: ADJUVANT THERAPY; ANALYTICAL METHOD; *BREAST*
CANCER; FEMALE; *METASTATIC CELLS*; NEOPLASTIC DISEASE; NODE-NEGATIVE;
ONCOLOGY; PATIENT; PROGNOSTIC FACTOR; PROGNOSTIC METHOD;
PROSTATE-SPECIFIC ANTIGEN; RECURRING TUMORS; REPRODUCTIVE SYSTEM
DISEASE/FEMALE; REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION; RNA;
THERAPEUTIC METHOD; VENOUS BLOOD

CONCEPT CODES:

16501 Reproductive System-General; Methods

24002 Neoplasms and Neoplastic Agents-General

34502 Immunology and Immunochemistry-General; Methods

BIOSYSTEMATIC CODES:

86215 Hominidae

9/5/5 (Item 5 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

10015756 BIOSIS NO.: 199598470674

Human peri-tumoral and lung fibroblasts produce paracrine motility factors
for recently established human sarcoma cell strains.

AUTHOR: Hu Mei; Pollock Raphael E; Nakamura Toshikazu; Nicolson Garth L(a)

AUTHOR ADDRESS: (a)Dep. Tumor Biol., Box 108, Univ. Texas M.D. Anderson
Cancer Cent., 1515 Holcombe Blvd., Houston, **USA

JOURNAL: International Journal of Cancer 62 (5):p585-592 1995

ISSN: 0020-7136

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Paracrine motogenic cytokines secreted by normal cells can stimulate metastatic cell invasion. For example, human fibroblasts secrete hepatocyte growth factor/scatter factor (HGF/SF), which stimulates paracrine migration of epithelial and certain carcinoma cells, and migration-stimulating factor (MSF), which stimulates autocrine migration of fibroblasts from certain *breast* carcinomas. We found that human peri-tumoral and lung fibroblasts secrete motility-stimulating activity for several recently established human sarcoma cell strains.

Motility of lung metastasis-derived SYN-1 sarcoma cells was preferentially stimulated by human lung and peri-tumoral fibroblast motility-stimulating factors (FMSFs). FMSFs were non-dialyzable, susceptible to trypsin and sensitive to dithiothreitol. Cycloheximide inhibited accumulation of FMSF activity in conditioned medium; however, addition of cycloheximide to the migration assay did not significantly affect motility-stimulating activity. Purified HGF/SF, rabbit anti-hHGF and RT-PCR analysis of peri-tumoral and lung fibroblast HGF/SF mRNA expression indicated that FMSF activity was unrelated to HGF/SF. Partial purification of FMSF by gel exclusion chromatography revealed several peaks of activity, suggesting multiple FMSF molecules or complexes. Since human soft tissue sarcomas have a distinctive hematogenous metastatic pattern (predominantly lung), FMSF may play a role in this process independent of HGF/SF.

DESCRIPTORS:

MAJOR CONCEPTS: Cell Biology; Endocrine System (Chemical Coordination and Homeostasis); Oncology (Human Medicine, Medical Sciences); Physiology;

Pulmonary Medicine (Human Medicine, Medical Sciences); Reproductive System (Reproduction); Skeletal System (Movement and Support)
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: Hominidae (Hominidae)
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; mammals; primates; vertebrates
MISCELLANEOUS TERMS: *BREAST* CARCINOMA; FIBROBLAST MOTILITY-STIMULATING FACTOR; HEPATIC GROWTH FACTOR; *METASTATIC CELL INVASION*; MIGRATION-STIMULATING FACTOR; SCATTER FACTOR

CONCEPT CODES:

02508 Cytology and Cytochemistry-Human
12100 Movement (1971-)
16006 Respiratory System-Pathology
16506 Reproductive System-Pathology
17002 Endocrine System-General
18006 Bones, Joints, Fasciae, Connective and Adipose Tissue-Pathology
24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects
10060 Biochemical Studies-General
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
BIOSYSTEMATIC CODES:
86215 Hominidae

9/5/6 (Item 6 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09710573 BIOSIS NO.: 199598165491
Characterization of transferrin-like factor 3 and its expression analysis in metastatic *breast* cancer cells.
AUTHOR: Jia L B; Cavanaugh P G; Nicolson G L
AUTHOR ADDRESS: Dep. Tumor Biol., The Univ. Tex. M.D. Anderson Cancer Cent., Houston, TX 75555**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 36 (0):p83 1995
CONFERENCE/MEETING: Eighty-sixth Annual Meeting of the American Association for Cancer Research Toronto, Ontario, Canada March 18-22, 1995
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English
DESCRIPTORS:

MAJOR CONCEPTS: Cell Biology; Development; Genetics; Metabolism; Oncology (Human Medicine, Medical Sciences)
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: human (Hominidae)
BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; mammals; primates; vertebrates
MISCELLANEOUS TERMS: DEVELOPMENT; GENE EXPRESSION; HOMEOSTASIS; MEETING ABSTRACT; *METASTATIC CELL GROWTH*; METASTATIC POTENTIAL; PARACRINE GROWTH FACTOR
CONCEPT CODES:
02508 Cytology and Cytochemistry-Human
03508 Genetics and Cytogenetics-Human
13012 Metabolism-Proteins, Peptides and Amino Acids
13014 Metabolism-Nucleic Acids, Purines and Pyrimidines
24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects
24006 Neoplasms and Neoplastic Agents-Biochemistry
25508 Developmental Biology-Embryology-Morphogenesis, General
10062 Biochemical Studies-Nucleic Acids, Purines and Pyrimidines
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
BIOSYSTEMATIC CODES:
86215 Hominidae

9/5/7 (Item 7 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08526405 BIOSIS NO.: 199344076405

Nm23 ("Anti-metastatic") gene protein expression in screen-detected carcinoma-in situ of the *breast*?

AUTHOR: Stephenson T J(a); Royds J A(a); Rees R C; Shorthouse A J; Silcocks P B

AUTHOR ADDRESS: (a)Dep. Pathol., Univ. Sheffield Med. Sch., Beech Hill Rd.,
Sheffield S10 2RX**K

JOURNAL: Journal of Pathology 169 (SUPPL.):p167A 1993

CONFERENCE/MEETING: 166th Meeting of the Pathological Society of Great Britain and Ireland London, England, UK January 6-8, 1993

ISSN: 0022-3417

RECORD TYPE: Citation

LANGUAGE: English

DESCRIPTORS:

MAJOR CONCEPTS: Cell Biology; Genetics; Metabolism; Oncology (Human Medicine, Medical Sciences); Reproductive System (Reproduction)

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: human (Hominidae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; mammals; primates; vertebrates

MISCELLANEOUS TERMS: ABSTRACT; *METASTATIC CELL LINE*

CONCEPT CODES:

02508 Cytology and Cytochemistry-Human

03508 Genetics and Cytogenetics-Human

13014 Metabolism-Nucleic Acids, Purines and Pyrimidines

16506 Reproductive System-Pathology

24005 Neoplasms and Neoplastic Agents-Neoplastic Cell Lines

24006 Neoplasms and Neoplastic Agents-Biochemistry

00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals

10062 Biochemical Studies-Nucleic Acids, Purines and Pyrimidines

BIOSYSTEMATIC CODES:

86215 Hominidae

?s s9 and immortaliz?

7 S9

42060 IMMORTALIZ?

S10 0 S9 AND IMMORTALIZ?

?ds

Set	Items	Description
S1	70	METASTATIC CELL?
S2	0	S1 AND SV40
S3	0	S1 AND IMMORTALIZ?
S4	6	S1 AND SPREAD?
S5	3	RD (unique items)
S6	25029	EPIHELIAL CELL?
S7	0	S6 AND S1
S8	14	S1 AND BREAST
S9	7	RD (unique items)
S10	0	S9 AND IMMORTALIZ?

?s s1 and prostate cell?

70 S1

226 PROSTATE CELL?

S11 0 S1 AND PROSTATE CELL?

?s s1 and prostate

70 S1

252246 PROSTATE

S12 6 S1 AND PROSTATE

?rd

>>>Duplicate detection is not supported for File 340.

>>>Duplicate detection is not supported for File 344.

>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 447.
>>>Duplicate detection is not supported for File 349.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
S13 3 RD (unique items)
?t s13/5/all

13/5/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11788329 BIOSIS NO.: 199900034438

Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse *prostate*.

AUTHOR: Thomas Regi; Anderson Winston A; Raman Venu; Reddi A Hari(a)

AUTHOR ADDRESS: (a)Cent. Tissue Regeneration Repair, Dep. Orthopedic Surg., Univ. Calif. Davis, 4635 Second Ave., R**USA

JOURNAL: Prostate 37 (4):p236-245 Dec. 1, 1998

ISSN: 0270-4137

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: BACKGROUND. What is the molecular basis of the osteotrophic action of prostatic metastases? Demineralized bone matrix has the potential to induce new bone formation. The identification of bone morphogenetic proteins (BMPs) as the primary inducers of new bone formation in demineralized bone matrix has set the stage for studying *prostate* cancer-bone interrelationships. We have hypothesized that BMPs may be expressed in *prostate* and may be involved in the osteotrophic actions of metastatic *prostate* cancer cells. METHODS. Using polymerase chain reaction (PCR)-based quantitation, this study examined the presence of BMPs in mouse *prostate* and their potential regulation by orchidectomy and androgen replacement. RESULTS. BMP-7 and BMP-4 genes were expressed in mouse *prostate*. Quantitative PCR *prostate*. CONCLUSIONS. The regulated expression of BMP-7 mRNA in the *prostate* suggests that BMP-7 may explain in part the stimulation of bone formation and osteosclerosis by metastatic *prostate* adenocarcinoma.

REGISTRY NUMBERS: 58-22-0: TESTOSTERONE; 521-18-6: DIHYDROTESTOSTERONE

DESCRIPTORS:

MAJOR CONCEPTS: Genetics; Reproductive System (Reproduction); Skeletal System (Movement and Support); Tumor Biology; Urinary System (Chemical Coordination and Homeostasis)

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: mouse (Muridae)--male, strain-CD1

ORGANISMS: PARTS ETC: bone--new formation, skeletal system; demineralized bone matrix--skeletal system; *prostate*--reproductive system

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates

DISEASES: osteosclerosis--bone disease; *prostate* cancer--*metastatic cells*, neoplastic disease, urologic disease, reproductive system disease/male, osteoporotic action

CHEMICALS & BIOCHEMICALS: androgen--replacement; bone morphogenetic protein 7--androgen-dependent gene expression; dihydrotestosterone; testosterone; mouse bone morphogenetic protein 4 gene (Muridae)--androgen-dependent gene expression; mouse bone morphogenetic protein 7 gene (Muridae)--androgen-dependent gene expression, messenger RNA level

METHODS & EQUIPMENT: orchectomy--analytical method; polymerase chain reaction--DNA amplification method

ALTERNATE INDEXING: Osteosclerosis (MeSH); Prostatic Neoplasms (MeSH)

CONCEPT CODES:

24002 Neoplasms and Neoplastic Agents-General

03506 Genetics and Cytogenetics-Animal
10504 Biophysics-General Biophysical Techniques
16501 Reproductive System-General; Methods
17002 Endocrine System-General
10060 Biochemical Studies-General

BIOSYSTEMATIC CODES:

86375 Muridae

13/5/2 (Item 2 from file: 5)
DIALOG(R) File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

10612768 BIOSIS NO.: 199699233913

Reverse transcriptase-polymerase chain reaction for *prostate*-specific antigen may be a prognostic indicator in breast cancer.

AUTHOR: Lehrer S(a); Terk M; Piccoli S P; Song H K; Lavagnini P; Luderer A A

AUTHOR ADDRESS: (a)Radiation Oncol., Box 1236, Mount Sinai Med. Cent., New York, NY 10029**USA

JOURNAL: British Journal of Cancer 74 (6):p871-873 1996

ISSN: 0007-0920

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Among women with node-negative breast cancer and small turnouts, it is important to identify those with turnouts that will recur, so that they may receive adjuvant therapy, while sparing those with turnouts that will not recur the hazards of adjuvant treatment. A reverse transcriptase-polymerase chain reaction (RT-PCR) for *prostate*-specific antigen (PSA) may be used to identify circulating metastatic cells in patients with *prostate* cancer. Approximately 30% of breast cancer cells also produce PSA. Therefore, we tested the PSA RT-PCR assay on blood specimens from women with breast cancer. We evaluated 78 women at Mount Sinai Medical Center with histologically confirmed breast cancer. Venous blood (5 CM-3) from the women was collected in ethylene diaminetetraacetic acid (EDTA)-treated collection tubes and approximately 400 ng of RNA from each sample was subjected to an RT-PCR. We were able to detect the amplified PSA fragment in 18 of 78 women with breast cancer; 7 of the 18 women with the PSA fragment had localized, small, node-negative tumours, both oestrogen receptor (ER) positive and ER negative. We could not detect the amplified PSA fragment in 20 normal women and 22 normal men. We conclude that PSA RT-PCR may be a useful method for determining the presence of circulating metastatic cells in some women with node-negative breast cancer, and therefore the potential for these women to develop recurrent disease and thus benefit from adjuvant therapy.

DESCRIPTORS:

MAJOR CONCEPTS: Immune System (Chemical Coordination and Homeostasis); Oncology (Human Medicine, Medical Sciences); Reproductive System (Reproduction)

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: human (Hominidae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; mammals; primates; vertebrates

MISCELLANEOUS TERMS: ADJUVANT THERAPY; ANALYTICAL METHOD; BREAST CANCER ; FEMALE; *METASTATIC CELLS*; NEOPLASTIC DISEASE; NODE-NEGATIVE; ONCOLOGY; PATIENT; PROGNOSTIC FACTOR; PROGNOSTIC METHOD; *PROSTATE*-SPECIFIC ANTIGEN; RECURRING TUMORS; REPRODUCTIVE SYSTEM DISEASE/FEMALE ; REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION; RNA; THERAPEUTIC METHOD; VENOUS BLOOD

CONCEPT CODES:

16501 Reproductive System-General; Methods

24002 Neoplasms and Neoplastic Agents-General

34502 Immunology and Immunochemistry-General; Methods
BIOSYSTEMATIC CODES:
86215 Hominidae

13/5/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08590946 BIOSIS NO.: 199345009021

Expression of tissue inhibitor of metallo-proteinase (TIMP) and collagenase in *prostate* cell lines with different invasive potential.

AUTHOR: Freeman Michael R; Moses Marsha A

AUTHOR ADDRESS: Boston, MA**USA

JOURNAL: Journal of Urology 149 (4 SUPPL.):p377A 1993

CONFERENCE/MEETING: Eighty-eighth Annual Meeting of the AUA (American Urological Association) San Antonio, Texas, USA May 15-20, 1993

ISSN: 0022-5347

RECORD TYPE: Citation

LANGUAGE: English

REGISTRY NUMBERS: 9001-12-1: COLLAGENASE

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Enzymology (Biochemistry and Molecular Biophysics); Reproductive System (Reproduction); Tumor Biology; Urinary System (Chemical Coordination and Homeostasis)

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: rat (Muridae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates; rodents; vertebrates

CHEMICALS & BIOCHEMICALS: COLLAGENASE

MISCELLANEOUS TERMS: ABSTRACT; EXTRACELLULAR MATRIX BARRIER; MATRIX

REGULATORY FACTORS; *METASTATIC CELL*; *PROSTATE* GROWTH

CONCEPT CODES:

10506 Biophysics-Molecular Properties and Macromolecules

10808 Enzymes-Physiological Studies

15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial System

15506 Urinary System and External Secretions-Pathology

16506 Reproductive System-Pathology

24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects

24006 Neoplasms and Neoplastic Agents-Biochemistry

00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals

02506 Cytology and Cytochemistry-Animal

10064 Biochemical Studies-Proteins, Peptides and Amino Acids

BIOSYSTEMATIC CODES:

86375 Muridae

?s disseminat?

S14 157976 DISSEMINAT?

?s s14 and epithelial

157976 S14

535234 EPITHELIAL

S15 3586 S14 AND EPITHELIAL

?s s15 and cell?

Processing

>>>File 348 processing for CELL? stopped at CELLULOSEPAPIERPRODUKT

Processing

Processed 10 of 14 files ...

Processing

>>>File 349 processing for CELL? stopped at CELLSX24H

Processing

Completed processing all files

3586 S15

11337170 CELL?

```

S16      3189  S15 AND CELL?
? s s16 and immortal?
            3189  S16
            49881  IMMORTAL?
S17      208  S16 AND IMMORTAL?
?s sv40
S18      57270  SV40
?s s17 and s18
            208  S17
            57270  S18
S19      101  S17 AND S18

?rd
>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 344.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 447.
>>>Duplicate detection is not supported for File 349.

>>>Records from unsupported files will be retained in the RD set.
...examined 50 records (50)
...examined 50 records (100)
...completed examining records
Processing
S20      95  RD (unique items)

?ds

Set      Items  Description
S1       70    METASTATIC CELL?
S2       0     S1 AND SV40
S3       0     S1 AND IMMORTALIZ?
S4       6     S1 AND SPREAD?
S5       3     RD (unique items)
S6       25029  EPITHELIAL CELL?
S7       0     S6 AND S1
S8       14    S1 AND BREAST
S9       7     RD (unique items)
S10      0     S9 AND IMMORTALIZ?
S11      0     S1 AND PROSTATE CELL?
S12      6     S1 AND PROSTATE
S13      3     RD (unique items)
S14      157976  DISSEMINAT?
S15      3586   S14 AND EPITHELIAL
S16      3189   S15 AND CELL?
S17      208    S16 AND IMMORTAL?
S18      57270   SV40
S19      101    S17 AND S18
S20      95     RD (unique items)

?s s20 and oncogene
            95  S20
            258524  ONCOGENE
S21      66    S20 AND ONCOGENE

?s s21 and cytokine
            66  S21
            334578  CYTOKINE
S22      49    S21 AND CYTOKINE

?s bone marrow
S23      132104  BONE MARROW

?s s22 and s23
            49  S22
            132104  S23
S24      0     S22 AND S23

?s s22 and exudate
            49  S22
            35218   EXUDATE
S25      1     S22 AND EXUDATE

?t s25/5/1

```

00577039

IMPROVED METHODS FOR TRANSDUCING *CELLS***METHODES AMELIOREES DE TRANSDUCTION CELLULAIRE****Patent Applicant/Assignee:**BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM, BOARD OF REGENTS, THE
UNIVERSITY OF TEXAS SYSTEM , 201 West 7th Street, Austin, TX 78701 , US**Inventor(s):**FIDLER Isaiah J, FIDLER, Isaiah, J. , Kingwood, TX , US
DONG Zhongyun, DONG, Zhongyun , Houston, TX , US
KUMAR Rakesh, KUMAR, Rakesh , Houston, TX , US**Patent and Priority Information (Country, Number, Date):**Patent: WO 9822605 A1 19980528
Application: WO 97US21475 19971119 (PCT/WO US9721475)
Priority Application: US 9631330 19961120

Designated States: CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

Main International Patent Class: C12N-015/85;

International Patent Class: C12N-015/86; C12Q-001/170; C12Q-001/68;
C07K-001/00; A61K-048/00;

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 50515

English Abstract

Disclosed are compositions and methods for inhibiting the expression and/or activity of endogenous β -interferon in *cells* targeted for transduction with viral vectors, particularly adenoviral vectors.

Therefore, also provided are improved methods for treatment of genetically-based diseases by gene therapy. Also disclosed are methods for the treatment of neovascularization-related diseases, for example, cancer, by the production *in vivo* of angiostatin, which inhibits the formation of new blood vessels. In particular embodiments, this is accomplished by transduction of macrophages *ex vivo* with a GM-CSF gene, thereby inducing the secretion of macrophage metalloelastase, which converts plasminogen to angiostatin. The transduced macrophages, when administered, naturally home to tumor sites to effectively localize the therapeutic effect.

French Abstract

Compositions et methodes pour inhiber l'expression et/ou l'activite de l'interferon- β endogene dans des cellules ciblees pour une transduction avec des vecteurs viraux, en particulier avec des vecteurs d'adenovirus. L'invention concerne par consequent egalement des methodes de therapie genique ameliorees pour des maladies genetiques. L'invention porte egalement sur des methodes de traitement des maladies liees a une neovascularisation, par exemple le cancer, par la production *in vivo* d'angiostatine inhibant la formation nouveaux vaisseaux sanguins. Dans des modes de realisation particuliers, ce resultat est obtenu par transduction de macrophages *ex vivo* avec un gene GM- CSF, induisant la secretion de metallo-elastase de macrophage, laquelle convertit le plasminogene en angiostatine. Une fois administres, les macrophages transduits se dirigent naturellement vers les sites tumoraux, realisant un ciblage efficace de l'effet therapeutique.

?s s22

S26 49 S22

?rd

>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 344.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 447.
>>>Duplicate detection is not supported for File 349.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S27 49 RD (unique items)

?t s27/5/all

27/5/1 (Item 1 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00780426

**RETINOID RECEPTOR INTERACTING POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES
POLYNUCLEOTIDES, POLYPEPTIDES ET ANTICORPS INTERAGISSANT AVEC LES
RECEPTEURS DE RETINOIDES**

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven A, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)
SHI Yanggu, 437 West Side Drive, Apt. 102, Gaithersburg, MD 20878, US, US
(Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200112786 A1 20010222 (WO 0112786)

Application: WO 2000US22351 20000815 (PCT/WO US0022351)

Priority Application: US 99148757 19990816; US 2000189026 20000314

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-005/10

International Patent Class: C12N-015/12; C12N-015/63; C12N-015/64;
C07K-014/47

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 78017

English Abstract

The present invention relates to novel human RIP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human RIP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human RIP polypeptides.

French Abstract

La presente invention concerne des nouveaux polypeptides RIP humains et des acides nucleiques isoles contenant les regions codantes des genes codant pour ces polypeptides. L'invention concerne egalement des vecteurs, des cellules hotes, des anticorps et des methodes de recombinaison permettant de produire des polypeptides RIP humains. Cette invention concerne en outre des methodes diagnostiques et therapeutiques permettant de diagnostiquer et de traiter les troubles lies a ces nouveaux polypeptides RIP humains.

Legal Status (Type, Date, Text)
Publication 20010222 A1 With international search report.
Publication 20010222 A1 Before the expiration of the time limit for
amending the claims and to be republished in the
event of receipt of amendments.

27/5/2 (Item 2 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00780421

13 HUMAN COLON AND COLON CANCER ASSOCIATED PROTEINS
13 PROTEINES ASSOCIEES AU CANCER DU COLON ET AU COLON HUMAIN

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

BIRSE Charles E, 13822 Saddleview Drive, North Potomac, MD 20878, US, US
(Residence), GB (Nationality), (Designated only for: US)
ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200112781 A1 20010222 (WO 0112781)
Application: WO 2000US22157 20000811 (PCT/WO US0022157)
Priority Application: US 99148680 19990813

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-001/21

International Patent Class: C12N-015/12; C12N-015/63; C07K-014/435

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description
Claims

Fulltext Word Count: 114826

English Abstract

This invention relates to newly identified colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon cancer antigens", and the use of such colon antigens for detecting disorders of the gastrointestinal system, particularly the presence of colon cancer and colon cancer metastases. This invention relates to colon cancer antigens as well as vectors, host *cells*, antibodies directed to colon cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of colon cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

French Abstract

La presente invention concerne l'identification de polynucleotides lies au colon ou au cancer du colon et les polypeptides codes par ces

polynucleotides appeles ici de facon collective <=antigenes du cancer du colon>, et l'utilisation de ces antigenes du colon dans la detection des troubles du tube digestif, et plus particulierement de la presence du cancer du colon et de metastases du cancer du colon. Cette invention concerne des antigenes du cancer du colon, de meme que des vecteurs, des cellules hotes, des anticorps diriges contre ces antigenes du cancer du colon et des technique de recombinaison et de synthese permettant la production de ceux-ci. Cette invention concerne aussi des techniques diagnostiques permettant de detecter, traiter, prevenir et/ou de pronostiquer des pathologies liees au colon, notamment le cancer du colon, et des techniques therapeutiques permettant de traiter ces pathologies. Cette invention concerne encore des methodes de recherche permettant d'identifier des agonistes et des antagonistes des antigenes du cancer du colon de l'invention. Enfin cette invention traite de la facon d'inhiber la production et la fonction des polypeptides de l'invention.

Legal Status (Type, Date, Text)

Publication 20010222 A1 With international search report.

Publication 20010222 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

27/5/3 (Item 3 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00780416

18 HUMAN SECRETED PROTEINS

18 PROTEINES SECRETEES HUMAINES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:
SHI Yanggu, Apt. 102, 437 West Side Drive, Gaithersburg, MD 20878, US, US (Residence), CN (Nationality), (Designated only for: US)
YOUNG Paul E, 122 Beckwith Street, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)
EBNER Reinhart, 9906 Shelburne Terrace #316, Gaithersburg, MD 20878, US, US (Residence), DE (Nationality), (Designated only for: US)
SOPPET Daniel R, 15050 Stillfield Place, Centreville, VA 22020, US, US (Residence), US (Nationality), (Designated only for: US)
RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200112776 A2 20010222 (WO 0112776)

Application: WO 2000US22350 20000815 (PCT/WO US0022350)

Priority Application: US 99148759 19990816

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

English Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

French Abstract

La presente invention concerne de nouvelles protéines secrétées humaines et des acides nucléiques isolés contenant les régions codantes des gènes codant ces mêmes protéines ; elle concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison qui permettent de produire les protéines secrétées humaines ainsi que des procédés de diagnostic et de traitement qui sont utiles pour diagnostiquer et traiter des maladies, des troubles et/ou des pathologies liées à ces nouvelles protéines secrétées humaines.

Legal Status (Type, Date, Text)

Publication 20010222 A2 Without international search report and to be republished upon receipt of that report.

27/5/4 (Item 4 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00780338

**TGF-BETA RECEPTOR POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES
POLYNUCLEOTIDES, POLYPEPTIDES DU RECEPTEUR DU TGF-BETA ET ANTICORPS**

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)
NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence),
CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200112670 A1 20010222 (WO 0112670)

Application: WO 2000US21736 20000810 (PCT/WO US0021736)

Priority Application: US 99148682 19990813; US 99154887 19990920

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K-014/705

International Patent Class: C07K-014/715; C12N-005/10; C12N-015/12;
C12N-015/63; C12N-015/64

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 86849

English Abstract

The present invention relates to novel human TGF-beta receptor polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human TGF-beta receptor polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human TGF-beta receptor polypeptides.

French Abstract

La presente invention concerne des polypeptides du recepteur du TGF-beta humains et des acides nucleiques isoles contenant les regions codantes des genes codant pour ces polypeptides. Cette invention concerne aussi des vecteurs, des cellules hotes, des anticorps et des techniques de recombinaison permettant de produire ces polypeptides de recepteur du TGF-beta. Enfin cette invention concerne des techniques diagnostiques et therapeutiques utiles pour diagnostiquer et traiter les troubles lies a ces polypeptides du recepteur du TGF-beta humains.

Legal Status (Type, Date, Text)

Publication 20010222 A1 With international search report.

27/5/5 (Item 5 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00776636

**CALCIUM CHANNEL TRANSPORT POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES
POLYNUCLEOTIDES, POLYPEPTIDES ET ANTICORPS DE TRANSPORT DE CANAUX CALCIQUES**
Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)
NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence),
CN (Nationality), (Designated only for: US)
SHI Yang-gu, Apt. No. 102, 437 West Side Drive, Gaithersburg, MD 20878,
US, US (Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200108635 A2 20010208 (WO 0108635)
Application: WO 2000US20392 20000727 (PCT/WO US0020392)
Priority Application: US 99145958 19990728; US 99149446 19990818; US
2000189064 20000314

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: A61K

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 78566

English Abstract

The present invention relates to novel human calcium channel transport

polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human calcium channel transport polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human calcium channel transport polypeptides.

French Abstract

La presente invention concerne de nouveaux polypeptides de transport de canaux calciques humains, ainsi que des acides nucleiques isoles contenant les regions codantes des genes qui codent pour ces polypeptides. Cette invention concerne egalement des vecteurs, des cellules hotes, des anticorps et des methodes de recombinaison permettant de produire ces polypeptides de transport de canaux calciques humains. L'invention concerne enfin des methodes diagnostiques et therapeutiques qui permettent de diagnostiquer et de traiter les troubles lies a ces nouveaux polypeptides de transport de canaux calciques humains.

Legal Status (Type, Date, Text)

Publication 20010208 A2 Without international search report and to be republished upon receipt of that report.

27/5/6 (Item 6 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00776635

SERINE PROTEASES
SERINE PROTEASES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)
YOUNG Paul E, 122 Beckwith Street, Gaithersburg, MD 20878, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200108634 A2 20010208 (WO 0108634)
Application: WO 2000US16847 20000620 (PCT/WO US0016847)
Priority Application: US 99147005 19990803; US 99152935 19990909; US
99162979 19991101; US 2000189025 20000314

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: A61K

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 75323

English Abstract

The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes

encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.

French Abstract

L'invention concerne de nouveaux polypeptides de serine protease humaine et des acides nucleiques isoles contenant les regions codant les genes qui codent ces polypeptides. L'invention concerne egalement les vecteurs, cellules hotes, anticorps, et les procedes de recombinaison permettant de produire ces polypeptides de serine protease humaine. Enfin, l'invention concerne les procedes de diagnostic et les procedes therapeutiques qui servent a diagnostiquer et traiter les troubles lies a ces nouveaux polypeptides de serine protease humaine.

Legal Status (Type, Date, Text)

Publication 20010208 A2 Without international search report and to be republished upon receipt of that report.

27/5/7 (Item 7 from file: 349)

DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00775235

ABC TRANSPORT POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES
POLYNUCLEOTIDES, POLYPEPTIDES DE TRANSPORT DE CASSETTE DE FIXATION DE
L'ADENOSINE TRIPHOSPHATE (ABC) ET ANTICORPS

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)
NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence),
CN (Nationality), (Designated only for: US)
MOORE Paul E, 19005 Leatherbark Drive, Germantown, MD 20874, US, US
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200107658 A1 20010201 (WO 0107658)
Application: WO 2000US19736 20000720 (PCT/WO US0019736)
Priority Application: US 99145215 19990723; US 99149445 19990818; US
99164730 19991112

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12Q-001/68

International Patent Class: C07H-021/02

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 80856

English Abstract

The present invention relates to novel human ABC Transport polypeptides

and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human ABC Transport polypeptides. The invention further relates to diagnostic and therapeutic methods usefull for diagnosing and treating disorders related to these novel human ABC Transport polypeptides.

French Abstract

Cette invention a trait a de nouveaux polypeptides humains de transport d'ABC ainsi qu'a des acides nucleiques isoles contenant les regions codantes des genes codant ces polypeptides. Elle concerne egalement des vecteurs, des cellules hotes, des anticorps ainsi que des methodes de recombinaison permettant de produire ces polypeptides humains de transport d'ABC. Elle porte, de surcroit, sur des methodes diagnostiques et therapeutiques des plus utiles en matiere de diagnostic et de traitement de troubles lies a ces nouveaux polypeptides humains de transport d'ABC.

Legal Status (Type, Date, Text)

Publication 20010201 A1 With international search report.

27/5/8 (Item 8 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00775199

KERATINOCYTE DERIVED INTERFERON INTERFERON DERIVE DU KERATINOCYTE

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)
MOORE Paul A, 19005 Leatherbark Drive, Germantown, MD 20874, US, US
(Residence), GB (Nationality), (Designated only for: US)
LAFLEUR David W, 3142 Quesada Street, Washington, DC 20015, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

MARKS Michelle S, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200107608 A1 20010201 (WO 0107608)

Application: WO 2000US1239 20000120 (PCT/WO US0001239)

Priority Application: US 99358587 19990721; WO 99US16424 19990721

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-015/12

International Patent Class: C12N-015/20; C07K-014/435; C07K-014/455;
A61K-038/17; A61K-038/21

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 125320

English Abstract

The present invention relates to a novel KDI protein which is a member of

the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called "KDI". KDI polypeptides are also provided as are vectors, host *cells* and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of KDI activity. Also provided are therapeutic methods for treating immune system-related disorders.

French Abstract

L'invention concerne une nouvelle protéine KDI, membre de la famille des interférons. L'invention concerne plus particulièrement des molécules d'acide nucléique isolées codant pour un polypeptide interféron humain, appelé <= KDI >=. L'invention concerne également les polypeptides KDI, ainsi que des vecteurs, des cellules hôtes, et des procédés de recombinaison destinés à produire ces derniers. L'invention concerne en outre des méthodes de criblage destinées à l'identification d'agonistes et d'antagonistes de l'activité de KDI. L'invention concerne par ailleurs des méthodes thérapeutiques de traitement de maladies liées au système immunitaire.

Legal Status (Type, Date, Text)

Publication 20010201 A1 With international search report.

27/5/9 (Item 9 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00775093

26 HUMAN PROSTATE AND PROSTATE CANCER ASSOCIATED PROTEINS

PROSTATE HUMAINE 26 ET CANCER DE LA PROSTATE ASSOCIE AUX PROTEINES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

ROSEN Craig A, 9410 Key West Avenue, Rockville, MD 20850, US, US
(Residence), US (Nationality)

BIRSE Charles, 13822 Saddleview Drive, North Potomac, MD 20878, US, US
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200107476 A1 20010201 (WO 0107476)

Application: WO 2000US19666 20000720 (PCT/WO US0019666)

Priority Application: US 99144972 19990721; US 99148681 19990813; US
99149173 19990817; US 99158004 19991006; US 2000194689 20000405

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR

LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ

TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K-014/47

International Patent Class: C12N-005/10; C12N-005/16; C12N-015/12;
C12N-015/63; C12N-015/64

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 129721

English Abstract

The present invention relates to newly identified human prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides (prostate cancer antigens). Also provided are vectors, host cells, antibodies, and recombinant methods for producing human prostate cancer antigens. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human prostate cancer antigens.

French Abstract

L'invention concerne un cancer de la prostate humaine recemment identifie lie aux polynucleotides et les polypeptides codes par ces polynucleotides (antigenes du cancer de la prostate). Font aussi l'objet de cette invention des vecteurs, des cellules hotes, des anticorps et des techniques recombinantes permettant d'obtenir des antigenes du cancer de la prostate humaine. L'invention concerne aussi le diagnostic et le traitement utilises pour diagnostiquer et traiter les troubles lies a ces nouveaux antigenes du cancer de la prostate humaine.

Legal Status (Type, Date, Text)

Publication 20010201 A1 With international search report.

27/5/10 (Item 10 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00770128

KERATINOCYTE GROWTH FACTOR-2

FACTEUR 2 DE CROISSANCE DES KERATINOCYTES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

JIMENEZ Pablo, 3843 College Avenue, Elicott City, MD 21043, US, US (Residence), US (Nationality), (Designated only for: US)

DUAN D Roxanne, 5515 Northfield Road, Bethesda, MD 20817, US, US (Residence), US (Nationality), (Designated only for: US)

RAMPY Mark A, 10224 Wild Apple Circle, Montgomery Village, MD 20886, US, US (Residence), US (Nationality), (Designated only for: US)

MENDRICK Donna, 29112 Ridge Road, Mount Airy, MD 21771, US, US (Residence), US (Nationality), (Designated only for: US)

ZHANG Jun, 10100 Crestberry Place, Bethesda, MD 20817, US, US (Residence), CN (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

MOORE Paul A, 19005 Leatherbark Drive, Germantown, MD 20874, US, US (Residence), GB (Nationality), (Designated only for: US)

COLEMAN Timothy A, 7512 Boxberry Terrace, Gaithersburg, MD 20879, US, US (Residence), US (Nationality), (Designated only for: US)

GRUBER Joachim R, Apartment 1, 4501 Normandy, Dallas, TX 75205, US, US (Residence), DE (Nationality), (Designated only for: US)

DILLON Patrick J, 1055 Snipe Court, Carlsbad, CA 92009, US, US (Residence), US (Nationality), (Designated only for: US)

GENTZ Reiner L, 13608 Mount Prospect Drive, Rockville, MD 20850, US, US (Residence), DE (Nationality), (Designated only for: US)

Legal Representative:

STEFFE Eric K, Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, D.C. 20005-3934, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200102433 A1 20010111 (WO 0102433)

Application: WO 2000US18328 20000703 (PCT/WO US0018328)

Priority Application: US 99142343 19990702; US 99143648 19990714; US 99144024 19990715; US 99148628 19990812; US 99149935 19990819; US 99163375 19991103; US 99171677 19991222; US 2000198322 20000419; US

2000205417 20000519

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K-014/47

International Patent Class: C07K-014/475; C12N-005/10; C12N-015/12;
C12N-015/16; C12N-015/63; C12N-015/64; A61K-038/16; A61K-038/17;
A61K-038/18

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 129131

English Abstract

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

French Abstract

L'invention concerne: des polynucleotides nouvellement identifies, des polypeptides codes par ces derniers; l'utilisation de ces polynucleotides et polypeptides; et leur preparation. En particulier, le polypeptide de l'invention est un facteur de croissance des keratinocytes, parfois designe sous le nom de <=KGF-2>, comme c'est ici le cas, ou sous le nom de facteur 12 de croissance des fibroblastes (FGF-12). L'invention concerne egalement l'utilisation therapeutique du KGF-2 destine a favoriser ou a accelerer la cicatrisation, ainsi que des nouvelles formes mutantes du KGF-2, qui presentent une activite amelioree, une stabilite accrue, un meilleur rendement ou une meilleure solubilite.

Legal Status (Type, Date, Text)

Publication 20010111 A1 With international search report.

Publication 20010111 A1 With (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description.

27/5/11 (Item 11 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00764864

50 HUMAN SECRETED PROTEINS

50 PROTEINES HUMAINES SECRETEES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)

RUBEN Steven M, 18528 Heritage Hill Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)

KOMATSOULIS George A, 9518 Garwood Street, Silver Spring, MD 20901, US,
US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200077022 A1 20001221 (WO 0077022)

Application: WO 2000US15136 20000601 (PCT/WO US0015136)

Priority Application: US 99138629 19990611

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07H-021/00

International Patent Class: C07K-002/00; C12P-019/34; C12N-015/12

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 131158

English Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

French Abstract

La presente invention concerne de nouvelles proteines humaines secretees, ainsi que des acides nucleiques isoles contenant les regions codantes des genes codant pour ces proteines. L'invention concerne egalement des vecteurs, des cellules hotes, des anticorps, et des methodes de recombinaison permettant de produire ces proteines humaines secretees. L'invention concerne enfin des methodes diagnostiques et therapeutiques utilisees dans le diagnostic et le traitement de maladies, de troubles et/ou d'etats pathologiques associes a ces nouvelles proteines humaines secretees.

Legal Status (Type, Date, Text)

Publication 20001221 A1 With international search report.

27/5/12 (Item 12 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00762027 **Image available**
NOVEL TET REPRESSOR-BASED TRANSCRIPTIONAL REGULATORY PROTEINS
PROTEINES DE REGULATION TRANSCRIPTIONNELLE BASEES SUR UN REPRESSEUR TET
Patent Applicant/Inventor:

HILLEN Wolfgang, Maria-Gebbert-Strasse 17, D-91080 Uttenreuth, DE, DE
(Residence), DE (Nationality)

BUJARD Hermann, Remlerstrasse 9, D-69120 Heidelberg, DE, DE (Residence),
DE (Nationality)

Legal Representative:

HOLDCROFT James Gerald, Graham Watt & Co., 11 White Hart Parade,
Riverhead, Sevenoaks, Kent TN13 2BN, GB

Patent and Priority Information (Country, Number, Date):

Patent: WO 200075347 A2 20001214 (WO 0075347)

Application: WO 2000IB886 20000605 (PCT/WO IB0000886)

Priority Application: US 99137986 19990607

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-015/62

International Patent Class: C12N-015/85; C07K-014/16; A61K-048/00; C12N-015/00; A01K-067/027

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 32125

English Abstract

The present invention provides a panel of transcriptional activator fusion proteins which comprises both tetracycline controlled transactivator proteins and reverse tetracycline transactivator proteins. These transactivators have novel phenotypes such as altered basal transcriptional activity in the absence of doxycycline, altered induced transcriptional activity in the presence of doxycycline, or differential induction by tetracycline and analogs of tetracycline.

French Abstract

La presente invention concerne un ensemble de protéines de fusion d'activation transcriptionnelle qui comprend à la fois des protéines transactivatrices à régulation par tetracycline et des protéines transactivatrices à régulation inverse par tetracycline. Ces transactivateurs présentent de nouveaux phénotypes tels qu'une activité transcriptionnelle basale altérée en l'absence de doxycycline, une activité transcriptionnelle induite altérée en présence de doxycycline, ou une induction différentielle par la tetracycline et ses analogues.

Legal Status (Type, Date, Text)

Publication 20001214 A2 Without international search report and to be republished upon receipt of that report.

27/5/13 (Item 13 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00761204

ADAM POLYNUCLEOTIDES AND POLYPEPTIDES

POLYNUCLEOTIDES ET POLYPEPTIDES ADAM

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

WEI Ping, 19100 Old Baltimore Road, Brookeville, MD 20833, US, US (Residence), US (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

HASTINGS Gregg A, 31919 Richgrove Court, Westlake Village, CA 91361, US, US (Residence), US (Nationality), (Designated only for: US)

SHI Yanggu, 437 West Side Drive, Apt. 102, Gaithersburg, MD 20878, US, US (Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200073323 A2 20001207 (WO 0073323)

Application: WO 2000US14308 20000525 (PCT/WO US0014308)

Priority Application: US 99136388 19990527; US 99142930 19990709; US 2000178717 20000128

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 83618

English Abstract

The present invention relates to novel human ADAM polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human ADAM polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human ADAM polypeptides.

French Abstract

Cette invention a trait a de nouveaux polypeptides ADAM humains ainsi qu'a des acides nucleiques isoles renfermant les regions codantes des genes codant ces polypeptides. L'invention porte egalement sur des vecteurs, des cellules hotes, des anticorps et des techniques de recombinaison permettant de produire ces polypeptides ADAM humains. Elle concerne, de surcroit, des methodes diagnostiques et therapeutiques des plus utiles en matiere de diagnostic et de traitement de troubles lies a ces nouveaux polypeptides ADAM humains.

Legal Status (Type, Date, Text)

Publication 20001207 A2 Without international search report and to be republished upon receipt of that report.

27/5/14 (Item 14 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00759538

FIBROBLAST GROWTH FACTOR 11

FACTEUR 11 DE CROISSANCE DES FIBROBLASTES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

ALDERSON Ralph, 12125 Orchard View Road, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

MELDER Robert, 14407 Saturn Way, Boyds, MD 20841, US, US (Residence), US (Nationality), (Designated only for: US)

DUAN Roxanne D, 5515 Northfield Road, Bethesda, MD 20817, US, US (Residence), US (Nationality), (Designated only for: US)

HU Jing-Shan, 1247 Lake Side Drive, No. 3034, Sunnyvale, CA 94086, US, US
(Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200071715 A1 20001130 (WO 0071715)

Application: WO 2000US13331 20000516 (PCT/WO US0013331)

Priority Application: US 99135524 19990521

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-015/16

International Patent Class: C12N-015/18; C12N-015/63; C12N-001/21;
C12N-005/00; G01N-033/53; A61K-038/18; C07K-014/50; C07K-016/22

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 106367

English Abstract

The present invention relates to a novel human protein called Fibroblast Growth Factor 11, and isolated polynucleotides encoding this protein. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

French Abstract

La presente invention concerne une nouvelle protéine humaine appelée facteur 11 de croissance des fibroblastes ainsi que des polynucléotides isolés codant cette protéine. L'invention concerne des vecteurs, des cellules hôtes, des anticorps ainsi que des méthodes de recombinaison permettant la production de cette protéine humaine. L'invention concerne en outre des méthodes diagnostiques et thérapeutiques utiles pour diagnostiquer et traiter des troubles relatifs à cette nouvelle protéine humaine.

Legal Status (Type, Date, Text)

Publication 20001130 A1 With international search report.

27/5/15 (Item 15 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00759434

SEVEN TRANSMEMBRANE RECEPTOR GENES
GENES RECEPTEURS HEPTATRANSMEMBRANAIRES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence),
CN (Nationality), (Designated only for: US)

SOPPET Daniel R, 15050 Stillfield Place, Centreville, MD 22020, US, US
(Residence), US (Nationality), (Designated only for: US)

LI Yi, 1247 Lakeside Drive #3034, Sunnyvale, CA 94086, US, US (Residence)

, CN (Nationality), (Designated only for: US)
FAN Ping, Apartment 302, 335 West Side Drive, Gaithersburg, MD 20878, US,
US (Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200071584 A1 20001130 (WO 0071584)
Application: WO 2000US13737 20000519 (PCT/WO US0013737)
Priority Application: US 99135167 19990520; US 99143616 19990713; US
99152934 19990909; US 2000189029 20000314

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K-014/705

International Patent Class: C07K-016/28; C12N-001/21; C12N-005/10;
C12N-015/12

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 83590

English Abstract

The present invention relates to novel human 7TM polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human 7TM polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human 7TM polypeptides.

French Abstract

La presente invention concerne des nouveaux polypeptides 7TM humains et des acides nucleiques isolés contenant les régions de codage des gènes codant ces polypeptides. Elle concerne également des vecteurs, des cellules hôtes, des anticorps et des méthodes de recombinaison servant à produire des polypeptides 7TM humains. L'invention se rapporte aussi à des méthodes diagnostiques et thérapeutiques utilisées pour diagnostiquer et traiter les troubles liés à ces nouveaux polypeptides 7TM humains.

Legal Status (Type, Date, Text)

Publication 20001130 A1 With international search report.

Publication 20001130 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

27/5/16 (Item 16 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00759432

FIBROBLAST GROWTH FACTOR 14

FACTEUR 14 DE CROISSANCE DU FIBROBLASTE

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

ALDERSON Ralph, 12125 Orchard View Road, Gaithersburg, MD 20878, US, US

(Residence), US (Nationality), (Designated only for: US)
GREENE John M, 872 Diamond Drive, Gaithersburg, MD 20878, US, US
(Residence), US (Nationality), (Designated only for: US)
MELDER Robert, 921 Beacon Square Court, No. 254, Gaithersburg, MD 20878,
US, US (Residence), US (Nationality), (Designated only for: US)
DUAN D Roxanne, 5515 Northfield Road, Bethesda, MD 20817, US, US
(Residence), US (Nationality), (Designated only for: US)
DILLON Patrick J, 1055 Snipe Court, Carlsbad, CA 92009, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200071582 A1 20001130 (WO 0071582)
Application: WO 2000US13416 20000517 (PCT/WO US0013416)
Priority Application: US 99135166 19990520

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K-014/50

International Patent Class: C07K-016/22; A61K-038/18; C12N-001/21;
C12N-005/10; C12N-015/18; C12N-015/63; G01N-033/53

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 104112

English Abstract

The present invention relates to a novel human protein called Fibroblast Growth Factor 14, and isolated polynucleotides encoding this protein. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

French Abstract

L'invention concerne une nouvelle protéine humaine dénommée facteur 14 de croissance du fibroblaste, ainsi que des polynucléotides isolés, codant cette protéine. L'invention concerne encore des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison destinés à produire cette protéine humaine. L'invention concerne enfin des procédés diagnostiques et thérapeutiques, utiles pour diagnostiquer et traiter des pathologies associées à cette nouvelle protéine humaine.

Legal Status (Type, Date, Text)

Publication 20001130 A1 With international search report.

Publication 20001130 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

27/5/17 (Item 17 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00759303

FIBROBLAST GROWTH FACTOR 10

FACTEUR 10 DE CROISSANCE DES FIBROBLASTES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:

US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)
ALDERSON Ralph, 12125 Orchard View Road, Gaithersburg, MD 20878, US, US
(Residence), US (Nationality), (Designated only for: US)
MELDER Robert, 14407 Saturn Way, Boyds, MD 20841, US, US (Residence), US
(Nationality), (Designated only for: US)
DUAN D Roxanne, 5515 Northfield Road, Bethesda, MD 20817, US, US
(Residence), US (Nationality), (Designated only for: US)
HU Jing-Shan, 1247 Lake Side Drive, No. 3034, Sunnyvale, CA 94086, US, US
(Residence), CN (Nationality), (Designated only for: US)
GOCAYNE Jeannine D, 30 Eldwick Court, Potomac, MD 20854, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200071152 A1 20001130 (WO 0071152)
Application: WO 2000US13573 20000518 (PCT/WO US0013573)
Priority Application: US 99135523 19990521

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: A61K-038/18

International Patent Class: A61K-048/00; C07H-021/04; C07K-014/50;
C07K-016/22; C12N-015/00; C12N-015/63; C12N-015/85; C12Q-001/68;
G01N-033/53

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 101398

English Abstract

The present invention relates to a novel human protein called Fibroblast Growth Factor 10, and isolated polynucleotides encoding this protein. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

French Abstract

La presente invention se rapporte a une nouvelle proteine humaine appelee Facteur 10 de Croissance des Fibroblastes, et a des polynucleotides isoles codant cette proteine: Elle se rapporte egalement a des vecteurs, des cellules hotes et des anticorps ainsi qu'a des methodes de recombinaison permettant de produire cette proteine. L'invention se rapporte en outre a des methodes diagnostiques et therapeutiques qui permettent de diagnostiquer et de traiter des troubles associes a cette nouvelle proteine humaine.

Legal Status (Type, Date, Text)

Publication 20001130 A1 With international search report.

Publication 20001130 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

00758375 **Image available**

FIBROBLAST GROWTH FACTOR 13

FACTEUR DE CROISSANCE DES FIBROBLASTES 13

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

MELDER Robert, 921 Beacon Square Court, No. 254, Gaithersburg, MD 20878,
US, US (Residence), US (Nationality), (Designated only for: US)
DUAN Roxanne D, 5515 Northfield Road, Bethesda, MD 20817, US, US
(Residence), US (Nationality), (Designated only for: US)

ALDERSON Ralph, 12125 Orchard Road View Road, Gaithersburg, MD 20878, US,
US (Residence), US (Nationality), (Designated only for: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)

GREENE John M, 872 Diamond Drive, Gaithersburg, MD 20878, US, US
(Residence), US (Nationality), (Designated only for: US)

GRUBER Joachim R, 4501 Normandy Apartment #1, Dallas, TX 75205, US, US
(Residence), DE (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200071567 A2 20001130 (WO 0071567)

Application: WO 2000US40080 20000504 (PCT/WO US0040080)

Priority Application: US 99132923 19990506

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 110132

English Abstract

The present invention relates to a novel human protein called Fibroblast Growth Factor 13, and isolated polynucleotides encoding this protein. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

French Abstract

La presente invention concerne une nouvelle protéine humaine désignée sous le nom de facteur de croissance des fibroblastes 13, et des polynucléotides isolés codant pour cette protéine. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps, et des méthodes de recombinaison servant à produire cette protéine humaine. L'invention concerne enfin des méthodes diagnostiques et thérapeutiques servant à diagnostiquer et à traiter des troubles liés à cette nouvelle protéine humaine.

Legal Status (Type, Date, Text)

Publication 20001130 A2 Without international search report and to be republished upon receipt of that report.

00757839

TM4SF RECEPTORS

RECEPTEURS TM4SF

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

FAN Ping, 13 Lake Potomac Court, Potomac, Maryland 20854, US, US (Residence), CN (Nationality), (Designated only for: US)

ROSCHKE Viktor, 13844 Lambertina Place, Rockville, MD 20850, US, US (Residence), RU (Nationality), (Designated only for: US)

SHI Yanggu, Apartment 102, 437 West Side Drive, Gaithersburg, MD 20878, US, US (Residence), CN (Nationality), (Designated only for: US)

KOMATSOULIS George A, 9518 Garwood Street, Silver Spring, MD 20901, US, US (Residence), US (Nationality), (Designated only for: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200070076 A1 20001123 (WO 0070076)

Application: WO 2000US13504 20000518 (PCT/WO US0013504)

Priority Application: US 99135122 19990519; US 99137797 19990603; US 99138573 19990611; US 99149447 19990818; US 2000178770 20000128

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12P-021/06

International Patent Class: C12P-021/04; C12N-015/74; C12N-005/00; C12N-005/02; C12N-001/20; C12N-015/00; C12N-015/09; C12N-015/63; C12N-015/70; C07K-001/00; C07K-014/00; C07K-017/00; C07H-021/04

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 82380

English Abstract

The present invention relates to novel human TM4SF polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human TM4SF polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders relates to these novel human TM4SF polypeptides.

French Abstract

La presente invention concerne des nouveaux polypeptides humains TM4SF et des acides nucleiques isoles contenant les regions codees des genes codant de tels polypeptides. Cette invention porte egalement sur des vecteurs, cellules hotes, anticorps, et methodes de recombinaison

permettant de produire des polypeptides humains TM4SF. Elle a trait, en outre, a methodes diagnostiques et therapeutiques utiles au traitement et diagnostic de troubles lies a ces nouveaux polypeptides humains TM4SF.

Legal Status (Type, Date, Text)

Publication 20001123 A1 With international search report.

Publication 20001123 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

27/5/20 (Item 20 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00756042

SERINE PROTEASES

SERINE PROTEASES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

SHI Yanggu, Apartment 102, 437 West Side Drive, Gaithersburg, MD 20878, US, US (Residence), CN (Nationality), (Designated only for: US)

YOUNG Paul E, 122 Beckwith Street, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200068247 A2 20001116 (WO 0068247)

Application: WO 2000US12207 20000505 (PCT/WO US0012207)

Priority Application: US 99133239 19990507; US 99135163 19990520; US 99147005 19990803; US 99152935 19990909; US 99162979 19991101

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 82831

English Abstract

The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.

French Abstract

La presente invention concerne de nouveaux polypeptides de serine protease ainsi que des acides nucleiques isoles comprenant les zones de

codage des genes codant ces polypeptides. L'invention concerne également des vecteurs, des cellules hotes, des anticorps et des procédés de recombinaison servant à produire des polypeptides de serine protéase. L'invention se rapporte aussi à des méthodes diagnostiques et thérapeutiques utilisées dans le diagnostic et le traitement de troubles liés à ces nouveaux polypeptides de serine protéase humaine.

Legal Status (Type, Date, Text)

Publication 20001116 A2 Without international search report and to be republished upon receipt of that report.

27/5/21 (Item 21 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00755908

FIBROBLAST GROWTH FACTOR 15

FACTEUR DE CROISSANCE DES FIBROBLASTES (FGF) 15

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

GREENE John M, 872 Diamond Drive, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

DUAN Roxanne D, 5515 Northfield Road, Bethesda, MD 20817, US, US (Residence), US (Nationality), (Designated only for: US)

ALDERSON Ralph, 12125 Orchard View Road, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

MELDER Robert, 921 Beacon Square Court #254, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200067775 A1 20001116 (WO 0067775)

Application: WO 2000US12350 20000504 (PCT/WO US0012350)

Priority Application: US 99132924 19990506

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: A61K-038/18

International Patent Class: A61K-048/00; C07H-021/04; C07K-014/50; C07K-016/22; C12N-015/00; C12N-015/63; C12N-015/85; C12Q-001/68; G01N-033/53

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 107702

English Abstract

The present invention relates to a novel human protein called Fibroblast Growth Factor 15, and isolated polynucleotides encoding this protein. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

French Abstract

L'invention concerne une nouvelle protéine humaine appelée FGF 15, et des polynucléotides isolés codant cette protéine. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison permettant d'élaborer ladite protéine. L'invention concerne en outre des procédés diagnostiques et thérapeutiques utiles pour l'établissement d'un diagnostic et la mise en place d'un traitement en cas de troubles liés à cette nouvelle protéine humaine.

Legal Status (Type, Date, Text)

Publication 20001116 A1 With international search report.

Publication 20001116 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

27/5/22 (Item 22 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00751001

GALECTIN 11

GALECTINE 11

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

LAJOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, 10355 Science Center Drive, San Diego, CA 92121, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

NI Jian, 5502 Manorfield, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

GENTZ Reiner L, 13608 Mount Prospect Drive, Rockville, MD 20850, US, US (Residence), DE (Nationality), (Designated only for: US)

LUI Fu-Tong, 4351 Mensha Place, San Diego, CA 92130, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

KLEIN Jonathan L, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200063221 A2 20001026 (WO 0063221)

Application: WO 2000US10714 20000421 (PCT/WO US0010714)

Priority Application: US 99130390 19990421; US 99169932 19991210

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07H-005/00

International Patent Class: C07H-005/04; C07H-019/00; C07H-021/00; C07H-021/02; C07H-021/04; C07K-001/00; C07K-001/04; C07K-004/00; C07K-004/12; C07K-005/00; C07K-017/00; C07K-017/02; C07K-017/04; C07K-017/08; C07K-016/00; C07K-016/18; G01N-033/53; G01N-033/567; A61K-038/00; A61K-038/04; A61K-038/05; A61K-038/06; A61K-038/07; A61K-038/08; A61K-038/10; A61K-038/14; A61K-038/16

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 107618

Legal Status (Type, Date, Text)

Publication 20001026 A2 With declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority.

27/5/23 (Item 23 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00749489

BONE MORPHOGENIC PROTEINS

PROTEINES MORPHOGENIQUES OSSEUSES BMP

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

KOMATSOULIS George, 9518 Garwood Street, Silver Spring, MD 20901, US, US (Residence), US (Nationality), (Designated only for: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

SHI Yanggu, 437 West Side Drive, Apt. 102, Gaithersburg, MD 20878, US, US (Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200061774 A2 20001019 (WO 0061774)

Application: WO 2000US9028 20000406 (PCT/WO US0009028)

Priority Application: US 99128701 19990409; US 99130693 19990423; US 99131672 19990429; US 99138632 19990611; US 99147020 19990803; US 99152933 19990909

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12P

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 84233

English Abstract

The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

French Abstract

L'invention concerne des nouveaux polypeptides BMP humains et des acides nucleiques contenant les regions codantes des genes codant pour lesdits polypeptides. Elle porte également sur des vecteurs, sur des cellules

hotes, sur des anticorps et sur des methodes de recombinaison pour la production de polypeptides BMP humains. Elle se rapporte encore a des methodes diagnostiques et therapeutiques utiles pour le diagnostic et le traitement de troubles lies a ces nouveaux polypeptides BMP humains.

Legal Status (Type, Date, Text)

Publication 20001019 A2 Without international search report and to be republished upon receipt of that report.

Examination 20010201 Request for preliminary examination prior to end of 19th month from priority date

27/5/24 (Item 24 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00749374

UNCOUPLING PROTEINS

PROTEINES BRULEUSES DE GRAISSES EXCEDENTAIRES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

KOMATSOULIS George, 9518 Garwood Street, Silver Spring, MD 20901, US, US (Residence), US (Nationality), (Designated only for: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

SOPPET Daniel R, 15050 Stillfield Place, Centreville, VA 22020, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200061614 A2 20001019 (WO 0061614)

Application: WO 2000US9534 20000406 (PCT/WO US0009534)

Priority Application: US 99128701 19990409; US 99142821 19990708; US 99149448 19990818; US 99164751 19991112

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K-014/00

International Patent Class: C12P-021/06

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 94506

Legal Status (Type, Date, Text)

Publication 20001019 A2 With declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority.

Examination 20010125 Request for preliminary examination prior to end of 19th month from priority date

27/5/25 (Item 25 from file: 349)

00744475

APOPTOSIS RELATED GENES

GENES LIES A L'APOPTOSE

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US
(Residence), US (Nationality), (Designated only for: US)
NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence),
CN (Nationality), (Designated only for: US)
YOUNG Paul A, 122 Beckwith Street, Gaithersburg, MD 20878, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200056752 A2 20000928 (WO 0056752)
Application: WO 2000US6642 20000315 (PCT/WO US0006642)
Priority Application: US 99126018 19990324; US 99139638 19990617; US
99149449 19990818

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07H-021/04

International Patent Class: C07K-014/435; A61K-038/17; C12Q-001/68;
C12N-015/11; C12N-015/63; C12N-001/21

Publication Language: English

Filing Language: English

Fulltext Availability:

 Detailed Description
 Claims

Fulltext Word Count: 89183

Legal Status (Type, Date, Text)

Publication 20000928 A2 With declaration under Article 17(2)(a); without
abstract; title not checked by the International
Searching Authority.

27/5/26 (Item 26 from file: 349)

00743045

HUMAN COLON CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER DU COLON CHEZ L'HOMME
Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US,
US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,

Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200055351 A1 20000921 (WO 0055351)

Application: WO 2000US5883 20000308 (PCT/WO US0005883)

Priority Application: US 99124270 19990312

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV

MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG

US UZ VN YU ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12P-021/04

International Patent Class: C12N-015/00; C07H-021/02

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 171641

English Abstract

This invention relates to newly identified colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such colon cancer antigens for detection, prevention and treatment of disorders of the colon, particularly the presence of colon cancer. This invention relates to the colon cancer antigens as well as vectors, host *cells*, antibodies directed to colon cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of colon cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

French Abstract

Cette invention porte sur des polynucleotides recemment identifies et associes au cancer du colon, et sur les polypeptides codes par ces polynucleotides et connus collectivement sous le nom <= d'antigenes du cancer du colon>=. L'invention porte egalement sur les sequences geniques completes associees et sur leurs produits d'expression, ainsi que sur l'utilisation de ces antigenes du cancer du colon dans la detection, la prevention et le traitement des pathologies specifiques d'un tissu telles que le cancer. Cette invention porte sur les antigenes du cancer, ainsi que sur les vecteurs, les cellules hotes, les anticorps diriges contre les antigenes du cancer et sur des procedes recombinants et synthetiques de production de ces anticorps. L'invention porte egalement sur des procedes de diagnostic permettant de diagnostiquer et traiter, prevenir et/ou etablir un pronostic de pathologies du colon telles que le cancer, et sur des procedes therapeutiques visant a traiter ces pathologies. Cette invention porte en outre sur des procedes de recherche automatique visant a identifier des agonistes et des antagonistes des antigenes du cancer du colon, et sur des procedes et/ou des compositions visant a inhiber la production et/ou la fonction des polypeptides de cette invention.

Legal Status (Type, Date, Text)

Publication 20000921 A1 With international search report.

00743044

**HUMAN CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER CHEZ L'HOMME**

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US
(Residence), US (Nationality), (Designated only for: US)

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US,
US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 2000055350 A1 20000921 (WO 0055350)

Application: WO 2000US5882 20000308 (PCT/WO US0005882)

Priority Application: US 99124270 19990312

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12P-019/34

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 223528

English Abstract

This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presence of cancer. This invention relates to the cancer antigens as well as vectors, host *cells*, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

French Abstract

Cette invention porte sur des polynucleotides recemment identifiés et associes au cancer specifique d'un tissu, et sur les polypeptides codes par ces polynucleotides et connus collectivement sous le nom <=d'antigènes du cancer>=. L'invention porte également sur les sequences geniques completes associees et sur leurs produits d'expression, ainsi que sur l'utilisation de ces antigènes du cancer specifique d'un tissu dans la detection, la prevention et le traitement des pathologies specifiques d'un tissu telles que le cancer. Cette invention porte sur les antigènes du cancer, ainsi que sur les vecteurs, les cellules hotes,

les anticorps dirigés contre les antigènes du cancer et sur des procédés recombinants et synthétiques de production de ces anticorps. L'invention porte également sur des procédés de diagnostic permettant de diagnostiquer et traiter, prévenir et/ou établir un pronostic de pathologies spécifiques d'un tissu telles que le cancer, et sur des procédés thérapeutiques visant à traiter ces pathologies. Cette invention porte en outre sur des procédés de recherche automatique visant à identifier des agonistes et des antagonistes des antigènes du cancer, et sur des procédés et/ou des compositions visant à inhiber la production et/ou la fonction des polypeptides de cette invention.

Legal Status (Type, Date, Text)

Publication 20000921 A1 With international search report.

Publication 20000921 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

27/5/28 (Item 28 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00743026

HUMAN PANCREAS AND PANCREATIC CANCER ASSOCIATED GENE SEQUENCES AND

POLYPEPTIDES

SEQUENCES DE GENES ET POLYPEPTIDES ASSOCIEES AU CANCER DU PANCREAS CHEZ

L'HOMME

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200055320 A1 20000921 (WO 0055320)

Application: WO 2000US5989 20000308 (PCT/WO US0005989)

Priority Application: US 99124270 19990312

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-015/12

International Patent Class: C12N-001/21; C12N-015/63

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 173445

English Abstract

This invention relates to newly identified pancreas or pancreatic cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "pancreatic cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such pancreatic cancer antigens for detection, prevention and treatment of disorders of

the pancreas, particularly the presence of pancreatic cancer. This invention relates to the pancreatic cancer antigens as well as vectors, host *cells*, antibodies directed to pancreatic cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of pancreatic cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

French Abstract

L'invention porte sur des polynucleotides et les polypeptides codes par eux nouvellement identifies connus sous l'appellation collective d'"antigenes du cancer du pancreas", sur les sequences completes de genes leur etant associees, sur leurs produits d'expression, ainsi que sur l'utilisation desdits "antigenes du cancer du pancreas" pour la detection, la prevention et le traitement d'affections du pancreas dont en particulier le cancer du pancreas. L'invention porte sur les antigenes du cancer du pancreas ainsi que sur des vecteurs, des cellules hotes, et des anticorps des antigenes du pancreas, et sur des procedes de recombinaison et de synthese permettant de les produire. L'invention porte egalement sur des methodes de diagnostic permettant de diagnostiquer, traiter, prevenir et/ou pronostiquer les affections du pancreas dont le cancer du pancreas, et sur des procedes therapeutiques permettant de les traiter. L'invention porte en outre sur des procedes de criblage permettant d'identifier les agonistes et antagonistes des antigenes du cancer du pancreas de l'invention, et sur des procedes et/ou compositions inhibant la production et/ou la fonction des polypeptides de l'invention.

Legal Status (Type, Date, Text)

Publication 20000921 A1 With international search report.
Publication 20000921 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

27/5/29 (Item 29 from file: 349)

DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00742916

**HUMAN LUNG CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER DU POUMON CHEZ
L'HOMME**

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200055180 A2 20000921 (WO 0055180)

Application: WO 2000US5918 20000308 (PCT/WO US0005918)

Priority Application: US 99124270 19990312

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG

US UZ VN YU ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07K

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 177094

English Abstract

This invention relates to newly identified lung or lung cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "lung cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such lung cancer antigens for detection, prevention and treatment of disorders of the lung, particularly the presence of lung cancer. This invention relates to the lung cancer antigens as well as vectors, host *cells*, antibodies directed to lung cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the lung, including lung cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of lung cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

French Abstract

Cette invention porte sur des polynucleotides recemment identifies et associes au cancer du poumon, et sur les polypeptides codes par ces polynucleotides et connus collectivement sous le nom <= d'antigenes du cancer du poumon>=. L'invention porte egalement sur les sequences geniques completes associees et sur leurs produits d'expression, ainsi que sur l'utilisation de ces antigenes du cancer du poumon dans la detection, la prevention et le traitement des pathologies du poumon telles que le cancer. Cette invention porte sur les antigenes du cancer du poumon, ainsi que sur les vecteurs, les cellules hotes, les anticorps diriges contre les antigenes du cancer du poumon et sur des procedes recombinants et synthetiques de production de ces anticorps. L'invention porte egalement sur des procedes de diagnostic permettant de diagnostiquer et traiter, prevenir et/ou etablir un pronostic de pathologies du poumon telles que le cancer, et sur des procedes therapeutiques visant a traiter ces pathologies. Cette invention porte en outre sur des procedes de recherche automatique visant a identifier des agonistes et des antagonistes des antigenes du cancer du poumon, et sur des procedes et/ou des compositions visant a inhiber la production et/ou la fonction des polypeptides de cette invention.

Legal Status (Type, Date, Text)

Publication 20000921 A2 Without international search report and to be republished upon receipt of that report.

Search Rpt 20010118 Late publication of international search report

27/5/30 (Item 30 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00742911

HUMAN PROSTATE CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES
SEQUENCES DE GENES ET POLYPEPTIDES ASSOCIEES AU CANCER DE LA PROSTATE DE
L'HOMME

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US,
US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200055174 A1 20000921 (WO 0055174)

Application: WO 2000US5988 20000308 (PCT/WO US0005988)

Priority Application: US 99124270 19990312

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07H-021/04

International Patent Class: C12N-015/63; C12N-015/85; C12N-015/09;
C07K-005/00; C07K-014/00; C12P-021/00

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 233031

English Abstract

This invention relates to newly identified prostate or prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "prostate cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such prostate cancer antigens for detection, prevention and treatment of disorders of the prostate, particularly the presence of prostate cancer. This invention relates to the prostate cancer antigens as well as vectors, host *cells*, antibodies directed to prostate cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of prostate cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

French Abstract

L'invention porte sur des polynucleotides et les polypeptides codes par eux nouvellement identifies connus sous l'appellation collective d'"antigenes du cancer de la prostate", sur les sequences completes de genes leur etant associees, sur leurs produits d'expression, ainsi que sur l'utilisation desdits "antigenes du cancer de la prostate" pour la detection, la prevention et le traitement d'affections de la prostate dont en particulier le cancer de la prostate. L'invention porte sur les antigenes du cancer de la prostate ainsi que sur des vecteurs, des cellules hotes, et des anticorps des antigenes de la prostate, et sur des procedes de recombinaison et de synthese permettant de les produire. L'invention porte egalement sur des methodes de diagnostic permettant de diagnostiquer, traiter, prevenir et/ou pronostiquer les affections de la prostate dont le cancer de la prostate, et sur des procedes therapeutiques permettant de les traiter. L'invention porte en outre sur des procedes de ciblage permettant d'identifier les agonistes et

antagonistes des antigenes du cancer de la prostate de l'invention, et sur des procedes et/ou compositions inhibant la production et/ou la fonction des polypeptides de l'invention.

Legal Status (Type, Date, Text)

Publication 20000921 A1 With international search report.

Examination 20010222 Request for preliminary examination prior to end of 19th month from priority date

27/5/31 (Item 31 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00742910

HUMAN BREAST AND OVARIAN CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES SEQUENCES ET POLYPEPTIDES GENIQUES ASSOCIES AU CANCER DES OVAIRES ET DU SEIN

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WALES Michele M, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 2000055173 A1 20000921 (WO 0055173)

Application: WO 2000US5881 20000308 (PCT/WO US0005881)

Priority Application: US 99124270 19990312

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07H-021/04

International Patent Class: C07K-005/04; C07K-016/00; G01N-033/53

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 170253

English Abstract

This invention relates to newly identified breast, ovarian, breast cancer and/or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "breast/ovarian cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such breast/ovarian cancer antigens for detection, prevention and treatment of disorders of the female reproductive system, particularly disorders of the breast and/or ovary, including the presence of breast cancer and/or ovarian cancer. This invention relates to the breast/ovarian cancer antigens as well as vectors, host *cells*, antibodies directed to breast/ovarian cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the female reproductive system, particularly disorders of the breast and/or ovary, including breast cancer and/or

ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of breast/ovarian cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

French Abstract

Cette invention porte sur des polynucleotides recemment identifies et associes au cancer du sein et/ou des ovaires, et sur les polypeptides codes par ces polynucleotides et connus collectivement sous le nom <= d'antigenes du cancer du sein/des ovaires >=. L'invention porte egalement sur les sequences geniques completes associees et sur leurs produits d'expression, ainsi que sur l'utilisation de ces antigenes du cancer du sein/des ovaires dans la detection, la prevention et le traitement des pathologies du systeme reproducteur feminin, notamment les pathologies du sein et/ou des ovaires telles que le cancer. Cette invention porte sur les antigenes du cancer du sein/des ovaires ainsi que sur les vecteurs, les cellules hotes, les anticorps diriges contre les antigenes et sur des procedes recombinants et synthetiques de production de ces anticorps. L'invention porte egalement sur des procedes de diagnostic permettant de diagnostiquer et traiter, prevenir et/ou etablir un pronostic de pathologies associees au systeme reproducteur feminin, notamment des pathologies du sein et/ou des ovaires telles que le cancer, et sur des procedes therapeutiques visant a traiter ces pathologies. Cette invention porte en outre sur des procedes de recherche automatique visant a identifier des agonistes et des antagonistes des antigenes du cancer du sein/des ovaires, et sur des procedes et/ou des compositions visant a inhiber la production et/ou la fonction des polypeptides de cette invention.

Legal Status (Type, Date, Text)

Publication 20000921 A1 With international search report.
Examination 20001130 Request for preliminary examination prior to end of 19th month from priority date

27/5/32 (Item 32 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00739884

HUMAN SERPIN PROTEINS

PROTEINES SERPINES HUMAINES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200052160 A1 20000908 (WO 0052160)

Application: WO 2000USS5082 20000229 (PCT/WO US0005082)

Priority Application: US 99122276 19990301; US 99124094 19990312; US 99149452 19990818

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-015/12

International Patent Class: C12N-005/10; C12P-021/02; C07K-014/47

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 74132

English Abstract

The present invention relates to novel human Serpin polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human Serpin polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human Serpin polypeptides.

French Abstract

L'invention concerne de nouveaux polypeptides serpins humains et des acides nucleiques isoles renfermant les regions de codage des genes codant de tels polypeptides. Elle concerne egalement des vecteurs, des cellules hotes, des anticorps, ainsi que des procedes de recombinaison permettant de produire des polypeptides serpins humains. L'invention se rapporte enfin a des procedes diagnostiques et therapeutiques utilises dans le traitement de troubles associes a ces nouveaux polypeptides serpins humains.

Legal Status (Type, Date, Text)

Publication 20000908 A1 With international search report.

Publication 20000908 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

Examination 20001116 Request for preliminary examination prior to end of 19th month from priority date

27/5/33 (Item 33 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00733357

NON-STOCHASTIC GENERATION OF GENETIC VACCINES AND ENZYMES

ELABORATION NON STOCHASTIQUE DE VACCINS GENETIQUES ET D'ENZYMES

Patent Applicant/Assignee:

DIVERSA CORPORATION, 10665 Sorrento Valley Road, San Diego, CA 92121, US,
US (Residence), US (Nationality)

Inventor(s):

SHORT Jay M, 320 Delage Drive, Encinitas, CA 92024, US

Legal Representative:

HAILE Lisa A, Gary Cary Ware & Friedenrich LLP, Suite 1600, 4365
Executive Drive, San Diego, CA 92121-2189, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200046344 A2 20000810 (WO 0046344)

Application: WO 2000US3086 20000204 (PCT/WO US0003086)

Priority Application: US 99246178 19990204

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N

Publication Language: English

Filing Language: English

Fulltext Availability:

 Detailed Description

 Claims

Fulltext Word Count: 168405

English Abstract

This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution)

French Abstract

La presente invention concerne des procedes de preparation de nouveaux polynucleotides et de polypeptides codes par des procedes non stochastiques d'evolution dirige (DirectEvolution)

Legal Status (Type, Date, Text)

Publication 20000810 A2 Without international search report and to be republished upon receipt of that report.

Search Rpt 20001228 Late publication of international search report

Examination 20010222 Request for preliminary examination prior to end of 19th month from priority date

27/5/34 (Item 34 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00730506 **Image available**

METALLOPROTEINASE ADAM 22

METALLOPROTEINASE ADAM 22

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

YOUNG Paul E, 122 Beckwith Street, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

MARKS Michelle S, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200043493 A2 20000727 (WO 0043493)

Application: WO 2000US1586 20000120 (PCT/WO US0001586)

Priority Application: US 99116927 19990122

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE

ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT

LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N

Publication Language: English

Filing Language: English

Fulltext Availability:

 Detailed Description

 Claims

Fulltext Word Count: 144190

English Abstract

The present invention relates to a novel metalloproteinase protein called ADAM 22. In particular, isolated nucleic acid molecules are provided

encoding the human ADAM 22 proteins. ADAM 22 polypeptides are also provided as are vectors, host *cells* and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of ADAM 22 activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of this metalloproteinase.

French Abstract

Cette invention concerne une protéine de métalloprotéinase dite ADAM 22. En particulier, l'invention concerne des molécules d'acide nucléique codant pour les protéines humaines ADAM 22. Elle s'applique également à des polypeptides ADAM 22, à des vecteurs et à des cellules hôtes ainsi qu'à des méthodes recombinantes relatives à leur obtention. L'invention concerne également des procédés de criblage permettant d'identifier des agonistes et des antagonistes de l'activité ADAM 22. Sont également traitées des méthodes de diagnostic pour la détection du cancer et des méthodes thérapeutiques pour le cancer et autres pathologies caractérisées par une production excessive ou insuffisante de cette métalloprotéinase.

Legal Status (Type, Date, Text)

Publication 20000727 A2 Without international search report and to be republished upon receipt of that report.
Publication 20000727 A2 With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.
Examination 20001026 Request for preliminary examination prior to end of 19th month from priority date
Declaration 20001102 Late publication under Article 17.2a

27/5/35 (Item 35 from file: 349)

DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00727926

HUMAN CHEMOKINE BETA-10 MUTANT POLYPEPTIDES POLYPEPTIDES MUTANTS DE CHIMIOKINE BETA-10 HUMAINE

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)
SMITHKLINE BEECHAM CORPORATION, 709 Swedeland Road, King of Prussia, PA 19406, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:
OLSEN Henrik S, 182 Kendrick Place, #24, Gaithersburg, MD 20878, US, US (Residence), DK (Nationality), (Designated only for: US)
LI Haodong, 11033 Rutledge Drive, Gaithersburg, MD 20878, US, US (Residence), CN (Nationality), (Designated only for: US)
ADAMS Mark D, 15205 Dufief Drive, North Potomac, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)
GENTZ Solange H L, 13608 Mount Prospect Drive, Rockville, MD 20850, US, US (Residence), BR (Nationality), (Designated only for: US)
ALDERSON Ralph, 12125 Orchard View Road, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)
LI Yuling, 12922 McCubbin Lane, Germantown, MD 20874, US, US (Residence), CN (Nationality), (Designated only for: US)

PARMELEE David, 11512 Parkedge Drive, Rockville, MD 20852, US, US (Residence), US (Nationality), (Designated only for: US)
WHITE John R, 332 Jennifer Drive, Coatsville, PA 19320, US, US (Residence), GB (Nationality), (Designated only for: US)
APPELBAUM Edward R, 830 Village Circle, Blue Bell, PA 19422, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

MARKS Michelle S, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200040726 A1 20000713 (WO 0040726)

Application: WO 2000US296 20000107 (PCT/WO US0000296)

Priority Application: US 99115439 19990108

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C12N-015/17

International Patent Class: C12N-015/00; C12N-015/03; C12N-015/63;
C07K-014/52; A61K-038/19

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 111052

English Abstract

Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

French Abstract

La presente invention concerne des polypeptides de chimiokine Beta-10 humaine et l'ADN (ARN) codant pour lesdits polypeptides, ainsi qu'une methode permettant de produire ces polypeptides a l'aide de techniques de recombinaison. L'invention concerne egalement des methodes d'utilisation de ces polypeptides de chimiokine dans le traitement de la leucemie, des infections chroniques, des maladies auto-immunes, des troubles de type fibrose, du psoriasis et dans la cicatrisation de lesions. L'invention concerne en outre des antagonistes diriges contre lesdits polypeptides de chimiokine, ainsi que leur utilisation therapeutique dans le traitement de la polyarthrite rhumatoide, des maladies auto-immunes et des maladies inflammatoires et infectieuses chroniques, des reactions allergiques, de la fievre independante des prostaglandines et de l'insuffisance medullaire.

Legal Status (Type, Date, Text)

Publication 20000713 A1 With international search report.

Examination 20001005 Request for preliminary examination prior to end of
19th month from priority date

27/5/36 (Item 36 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00719716 **Image available**

STIMULATION OF T *CELLS* AGAINST SELF ANTIGENS USING CTLA-4 BLOCKING AGENTS
STIMULATION DE LYMPHOCYTES T CONTRE DES AUTO-ANTIGENES AU MOYEN D'AGENTS
BLOQUANTS CTLA-4

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Suite 510, 2150 Shattuck
Avenue, Berkeley, CA 94720-1620, US, US (Residence), US (Nationality)

Inventor(s):

ALLISON James P, 920 Oxford Street, Berkeley, CA 94707, US
HURWITZ Arthur A, 7958 Everglades Drive, Manlius, NY 13104, US
VANELSAS Andrea, Tjalk 87, NL-1625 EG Hoorn, NL

Legal Representative:

TRECARTIN Richard F, Flehr, Hohbach, Test, Albritton & Herbert L.L.P.,
Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 2000032231 A1 20000608 (WO 0032231)
Application: WO 99US28739 19991203 (PCT/WO US9928739)
Priority Application: US 98110761 19981203

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: A61K-039/395

International Patent Class: A61K-039/00 -48/00; C07K-014/53; A61K-039/395;
A61K-039:00

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 22310

English Abstract

Stimulation of T *cells* to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-*cell* response against self antigens. This enhanced response is useful for the treatment of non-immunogenic and poorly-immunogenic tumors, as well as other medical conditions requiring selective tissue ablation.

French Abstract

La stimulation de lymphocytes T en reponse a des auto-antigenes s'obtient par blocage au moyen de la signalisation CTLA-4. On combine des agents bloquants CTLA-4 avec des preparations antigeniques, soit seuls, soit avec d'autres agents stimulant la reponse immunitaire, dans le cadre de strategies de co-stimulation pour rompre la tolerance immunitaire et stimuler et accentuer la reponse des lymphocytes T contre les auto-antigenes. Cette reponse plus marquee est utile pour le traitement de tumeurs non immunogenes ou faiblement immunogenes ainsi que pour diverses pathologies necessitant l'ablation selective de tissus.

Legal Status (Type, Date, Text)

Publication 20000608 A1 With international search report.

Publication 20000608 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

Examination 20000824 Request for preliminary examination prior to end of 19th month from priority date

27/5/37 (Item 37 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00716687

31 HUMAN SECRETED PROTEINS

31 PROTEINES HUMAINES SECRETEES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,

US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

NI Jian, 5502 Manorfield Road, Rockville, MD 20853, US, US (Residence), CN (Nationality), (Designated only for: US)

RUBEN Steven M, 18528 Heritage Hills Drive, Olney, MD 20832, US, US (Residence), US (Nationality), (Designated only for: US)

ROSEN Craig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US (Residence), US (Nationality), (Designated only for: US)

EBNER Reinhard, 9906 Shelburne Terrace #316, Gaithersburg, MD 20878, US, US (Residence), DE (Nationality), (Designated only for: US)

FLORENCE Kimberly A, 12805 Atlantic Avenue, Rockville, MD 20851, US, US (Residence), US (Nationality), (Designated only for: US)

YOUNG Paul E, 122 Beckwith Street, Gaithersburg, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

BIRSE Charles E, 13822 Saddleview Drive, North Potomac, MD 20878, US, US (Residence), GB (Nationality), (Designated only for: US)

CARTER Kenneth C, 11600 Brandy Hall Lane, North Potomac, MD 20878, US, US (Residence), US (Nationality), (Designated only for: US)

KOMATSOULIS George, 9518 Garwood Street, Silver Spring, MD 20901, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200029422 A1 20000525 (WO 0029422)

Application: WO 99US26409 19991109 (PCT/WO US9926409)

Priority Application: US 98108207 19981112

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07H-021/02

International Patent Class: C07H-019/00; C07H-021/04; C07H-021/00;

C12Q-001/68; G01N-033/53; C12P-021/06; C12P-021/08; C12N-015/00;

C12N-015/09; C12N-015/63; C12N-015/70; C12N-015/74; C07K-001/00;

C07K-014/00; C07K-017/00; C07K-016/00; A61K-038/00; A01N-061/00

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 99244

English Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host *cells*, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

French Abstract

La presente invention concerne de nouvelles protéines humaines secrétées et des acides nucléiques isolés contenant les régions codantes des gènes codant pour ces protéines. Cette invention concerne également des vecteurs, des cellules hôtes, des anticorps, et des procédés permettant de produire des protéines humaines secrétées par recombinaison. Cette invention concerne enfin des procédés diagnostiques et thérapeutiques utilisés pour diagnostiquer et traiter les troubles liés à ces nouvelles protéines humaines secrétées.

Legal Status (Type, Date, Text)
Publication 20000525 A1 With international search report.
Examination 20001005 Request for preliminary examination prior to end of
19th month from priority date

27/5/38 (Item 38 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00693640

98 HUMAN SECRETED PROTEINS
98 PROTEINES HUMAINES SECRETEES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, HUMAN GENOME SCIENCES, INC., 9410 Key West
Avenue, Rockville, MD 20850, US

Inventor(s):

KOMATSOULIS George A, KOMATSOULIS, George, A., 9518 Garwood Street,
Silver Spring, MD 20901, US

ROSEN Craig A, ROSEN, Craig, A., 22400 Rolling Hill Road, Laytonsville,
MD 20882, US

RUBEN Steven M, RUBEN, Steven, M., 18528 Heritage Hills Drive, Olney, MD
20832, US

DUAN Roxanne, DUAN, Roxanne, 5515 Northfield Road, Bethesda, MD 20817, US

MOORE Paul A, MOORE, Paul, A., 19005 Leatherbark Drive, Germantown, MD
20874, US

SHI Yanggu, SHI, Yanggu, Apartment 102, 437 West Side Drive,
Gaithersburg, MD 20878, US

LAFLEUR David, LAFLEUR, David, 3142 Quesada Street, N.W., Washington, DC
20015, US

WEI Ying-Fei, WEI, Ying-Fei, 242 Gravatt Drive, Berkeley, CA 94705, US

NI Jian, NI, Jian, 5502 Manorfield Road, Rockville, MD 20853, US

FLORENCE Kimberly A, FLORENCE, Kimberly, A., 12805 Atlantic Avenue,
Rockville, MD 20851, US

YOUNG Paul E, YOUNG, Paul, E., 122 Beckwith Street, Gaithersburg, MD
20878, US

BREWER Laurie A, BREWER, Laurie, A., Apartment 115, 410 Van Dyke Street,
St. Paul, MN 55119-4321, US

SOPPET Daniel R, SOPPET, Daniel, R., 15050 Stillfield Place, Centreville,
VA 22020, US

ENDRESS Gregory A, ENDRESS, Gregory, A., 9729 Clagett Farm Drive,
Potomac, MD 20854, US

EBNER Reinhard, EBNER, Reinhard, 9906 Shelburne Terrace &316,
Gaithersburg, MD 20878, US

OLSEN Henrik S, OLSEN, Henrik, S., 182 Kendrick Place &24, Gaithersburg,
MD 20878, US

MUCENSKI Michael, MUCENSKI, Michael, 3265 Mandale Drive, Cincinnati, OH
45239, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 0006698 A1 20000210 (WO 200006698)

Application: WO 99US17130 19990729 (PCT/WO US9917130)

Priority Application: US 9894657 19980730; US 9895486 19980806; US
9895455 19980812

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
MG MK MN MW NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US
UZ VN YU ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN GW ML MR NE SN TD TG

Main International Patent Class: C12N-001/21;

International Patent Class: C12N-005/10; C12N-015/11; C12N-015/12;
C12N-015/63; A61K-038/16; A61K-038/17; C07K-014/00; C07K-014/435;
C07K-016/00; G01N-033/50;

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

English Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

French Abstract

La presente invention concerne de nouvelles protéines humaines secrétées, ainsi que des acides nucléiques isolés contenant les régions codantes des gènes codant pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps, et des méthodes de recombinaison permettant de produire les protéines humaines secrétées. L'invention concerne enfin des méthodes diagnostiques et thérapeutiques utilisées dans le traitement de troubles associés à ces nouvelles protéines humaines secrétées.

Legal Status (Type, Date, Text)

Examination 20000608 Request for preliminary examination prior to end of 19th month from priority date

27/5/39 (Item 39 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00660397

ISOLATED STROMAL *CELLS* FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
CELLULES DU STROMA ISOLEES DESTINEES A ETRE UTILISEES DANS LE TRAITEMENT DES MALADIES DU SYSTEME NERVEUX CENTRAL

Patent Applicant/Assignee:

MCP HAHNEMANN UNIVERSITY, MCP HAHNEMANN UNIVERSITY, Suite 100, 3201 Arch Street, Philadelphia, PA 19104, US

Inventor(s):

PROCKOP Darwin J, PROCKOP, Darwin, J., 291 Locust Street, Philadelphia, PA 19106, US

STOKES David G, STOKES, David, G., 1632 Jill Road, Willow Grove, PA 19090, US

AZIZI S Ausim, AZIZI, S., Ausim, 3815 Stokley Street, Philadelphia, PA 19129, US

PHINNEY Donald G, PHINNEY, Donald, G., 1841 Webster Lane, Maple Glen, PA 19002, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9943286 A2 19990902

Application: WO 99US3897 19990224 (PCT/WO US9903897)

Priority Application: US 9828395 19980224

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Main International Patent Class: A61K-000/;

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 36109

English Abstract

Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal *cells* from the bone marrow sample, and administering the isolated stromal *cells* to the central nervous system of the human patient, wherein the presence of the isolated stromal *cells* in the brain effects treatment of the disease, disorder or condition. Stromal *cells* which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system.

French Abstract

L'invention concerne des procedes de traitement d'un patient humain souffrant d'une maladie, de troubles ou d'un etat pathologique du systeme nerveux central. Ces procedes consistent a obtenir un echantillon de moelle osseuse a partir d'un donneur humain, a isoler les cellules du stroma de cet echantillon de moelle osseuse; et a administrer les cellules du stroma isolees au systeme nerveux central du patient humain, la presence des cellules du stroma isolees dans le cerveau permettant le traitement de la maladie, des troubles ou de l'etat pathologique. Les cellules du stroma qui sont isolees peuvent etre cultivees in vitro, elles peuvent etre produites par genie genetique de maniere a obtenir des compositions therapeutiques, et/ou elles peuvent etre predifferentiees avant d'etre administrees dans le systeme nerveux central.

Legal Status (Type, Date, Text)

Examination 20000914 Request for preliminary examination prior to end of 19th month from priority date

27/5/40 (Item 40 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00654694 **Image available**

A NEW HUMAN TUMOR-ASSOCIATED GENE

NOUVEAU GENE HUMAIN ASSOCIE AUX TUMEURS

Patent Applicant/Assignee:

JOHN WAYNE CANCER INSTITUTE, JOHN WAYNE CANCER INSTITUTE , 2200 Santa Monica Boulevard, Santa Monica, CA 90404 , US

Inventor(s):

HOON David S B, HOON, David, S., B. , 2200 Santa Monica Boulevard, Santa Monica, CA 90404 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9937771 A1 19990729

Application: WO 99US1395 19990122 (PCT/WO US9901395)

Priority Application: US 9872126 19980122; US 99234685 19990121

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Main International Patent Class: C12N-015/12;

International Patent Class: C07K-014/47; C07K-016/18; G01N-033/53; C12N-005/20; C12Q-001/68; C12N-015/86; C12N-015/11; A61K-031/70; A61K-038/17; G01N-033/50;

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 48484

English Abstract

The present invention describes a novel tumor marker antigen encoded by a

gene designated as HOJ-1 (SEQ ID NO:1). In specific embodiment, the nucleic acid sequences disclosed herein are for use in the diagnosis and prognosis of cancer. Also provided are related protein and antibody compositions and various methods of use thereof, including methods for cancer diagnosis and treatment.

French Abstract

La presente invention concerne un nouvel antigene marqueur tumoral code par un gene denomme HOJ-1 (SEQ. ID. NO 1). Dans un mode de realisation specifique, les sequences d'acide nucleique de la presente invention s'utilisent pour le diagnostic et le pronostic du cancer. L'invention concerne egalement des compositions de proteines et d'anticorps associees, ainsi que plusieurs methodes d'utilisation de ces compositions, y compris des methodes de diagnostic et de traitement du cancer.

27/5/41 (Item 41 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00597100

COMPOSITIONS FOR TREATMENT OF DISORDERS INVOLVING PROGRAMMED *CELL* DEATH COMPOSITIONS DE TRAITEMENT D'AFFECTIONS IMPLIQUANT LA MORT CELLULAIRE PROGRAMMEE

Patent Applicant/Assignee:

YEDA RESEARCH AND DEVELOPMENT CO LTD, YEDA RESEARCH AND DEVELOPMENT CO.
LTD. , Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot , IL

Inventor(s):

KIMCHI Adi, KIMCHI, Adi , Hashalom Street 38, 43561 Raanana , IL
Patent and Priority Information (Country, Number, Date):

Patent: WO 9839429 A2 19980911

Application: WO 98IL102 19980303 (PCT/WO IL9800102)

Priority Application: US 97810712 19970303

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US
UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW ÄM AZ BY KG KZ MD RU TJ TM AT BE
CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG

Main International Patent Class: C12N-015/11;

International Patent Class: C12N-015/12; C07K-014/47; C12N-009/64;

C12Q-001/68; A61K-048/00;

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 29800

English Abstract

Use of a DNA sequence capable of inducing programmed *cell* death, in the preparation of a pharmaceutical composition for use in the treatment of a disease or a disorder associated with metastasizing pathological *cell* growth. Also described is the use of a DNA sequence capable of promoting non-*cytokine*-induced programmed *cell* death, in the preparation of a pharmaceutical composition useful in the treatment of a disease or a disorder associated with uncontrolled pathological *cell* growth, or in the treatment of a disease or a disorder associated with non-*cytokine* induced programmed *cell* death.

French Abstract

L'invention concerne l'utilisation d'une sequence d'ADN capable d'induire la mort cellulaire programmee, dans la preparation d'une composition pharmaceutique utile dans le traitement d'une maladie ou d'une affection associee a la croissance cellulaire pathologique metastasante.

L'invention concerne egalement l'utilisation d'une sequence d'ADN capable

de promouvoir la mort cellulaire programmee non induite par des cytokines, dans la preparation d'une composition pharmaceutique utile dans le traitement d'une maladie ou d'une affection associee a une croissance cellulaire pathologique non regulee, ou dans le traitement d'une maladie ou d'une affection associee a une mort cellulaire programmee non induite par des cytokines.

27/5/42 (Item 42 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00577039

IMPROVED METHODS FOR TRANSDUCING *CELLS*

METHODES AMELIOREES DE TRANSDUCTION CELLULAIRE

Patent Applicant/Assignee:

BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , 201 West 7th Street, Austin, TX 78701 , US

Inventor(s):

FIDLER Isaiah J, FIDLER, Isaiah, J. , Kingwood, TX , US

DONG Zhongyun, DONG, Zhongyun , Houston, TX , US

KUMAR Rakesh, KUMAR, Rakesh , Houston, TX , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9822605 A1 19980528

Application: WO 97US21475 19971119 (PCT/WO US9721475)

Priority Application: US 9631330 19961120

Designated States: CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

Main International Patent Class: C12N-015/85;

International Patent Class: C12N-015/86; C12Q-001/170; C12Q-001/68;

C07K-001/00; A61K-048/00;

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 50515

English Abstract

Disclosed are compositions and methods for inhibiting the expression and/or activity of endogenous β -interferon in *cells* targeted for transduction with viral vectors, particularly adenoviral vectors. Therefore, also provided are improved methods for treatment of genetically-based diseases by gene therapy. Also disclosed are methods for the treatment of neovascularization-related diseases, for example, cancer, by the production *i> in vivo* *of angiostatin, which inhibits the formation of new blood vessels. In particular embodiments, this is accomplished by transduction of macrophages *ex vivo* with a GM-CSF gene, thereby inducing the secretion of macrophage metalloelastase, which converts plasminogen to angiostatin. The transduced macrophages, when administered, naturally home to tumor sites to effectively localize the therapeutic effect.*

French Abstract

Compositions et methodes pour inhiber l'expression et/ou l'activite de l'interferon- β endogene dans des cellules ciblees pour une transduction avec des vecteurs viraux, en particulier avec des vecteurs d'adenovirus. L'invention concerne par consequent egalement des methodes de therapie genique ameliores pour des maladies genetiques. L'invention porte egalement sur des methodes de traitement des maladies liees a une neovascularisation, par exemple le cancer, par la production *in vivo* *d'angiostatine inhibant la formation nouveaux vaisseaux sanguins. Dans des modes de realisation particuliers, ce resultat est obtenu par transduction de macrophages *ex vivo* avec un gene GM- CSF, induisant la secretion de metallo-elastase de macrophage, laquelle convertit le plasminogene en angiostatine. Une fois administres, les macrophages transduits se dirigent naturellement vers les sites tumoraux, realisant un ciblage efficace de l'effet therapeutique.*

27/5/43 (Item 43 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00577025 **Image available**

**SURVIVIN, A PROTEIN THAT INHIBITS CELLULAR APOPTOSIS, AND ITS MODULATION
LA SURVIVINE, PROTEINE INHIBANT L'APOPTOSE CELLULAIRE, ET SA MODULATION**
Patent Applicant/Assignee:

YALE UNIVERSITY, YALE UNIVERSITY , 451 College Street, New Haven, CT
06510 , US

Inventor(s):

ALTIERI Dario C, ALTIERI, Dario, C. , 100 Reservoir Street, Hamden, CT
06517 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9822589 A2 19980528

Application: WO 97US21880 19971120 (PCT/WO US9721880)

Priority Application: US 9631435 19961120

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN
MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES
FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD
TG

Main International Patent Class: C12N-015/12;

International Patent Class: C07K-014/47; C07K-016/18; C12Q-001/68;
G01N-033/53; G01N-033/68; A61K-038/17; A61K-048/00;

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 25920

English Abstract

The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the Survivin family of proteins, methods for identifying agent that blocks Survivin mediated inhibition of cellular apoptosis, methods of using agent that block Survivin mediated inhibition or Survivin expression to modulate biological and pathological processes, and methods of assaying Survivin activity.

French Abstract

La presente invention concerne l'acide amine d'une proteine inhibant l'apoptose cellulaire, appelee ici proteine Survivine et des molecules d'acide nucleique codant la Survivine. Sur la base de cette divulgation, la presente invention fait etat d'une proteine Survivine isolee, de molecules d'acide codant la Survivine isolee, de procedes d'isolement d'autres membres de la famille de proteines Survivine, de procedes d'identification d'agents bloquant l'inhibition, induite par la Survivine, de l'apoptose cellulaire, de procedes d'utilisation d'agents bloquant l'inhibition induite par la Survivine ou l'expression de la Survivine pour moduler des processus biologiques et pathologiques, et de procedes d'evaluation de l'activite de la Survivine.

27/5/44 (Item 44 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00522680 **Image available**

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER

METHODES ET COMPOSITIONS POUR DIAGNOSTIQUER ET TRAITER DES CANCERS

Patent Applicant/Assignee:

BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM

CLAYMAN Gary L

Inventor(s):

CLAYMAN Gary L

Patent and Priority Information (Country, Number, Date):

Patent: WO 9720047 A1 19970605

Application: WO 96US19083 19961127 (PCT/WO US9619083)

Priority Application: US 957810 19951130

Designated States: AL AM AT AU BA BB BG CA CH CN CU CZ DE DK EE ES FI GB GE
HU IL IS JP KE KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG TJ TM TR TT UA UG US UZ KE LS MW SD SZ UG AM AZ BY KG KZ
MD RU TJ TM AT DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM GA GN ML MR TD TG

Main International Patent Class: C12N-015/12;

International Patent Class: A61K-048/00;

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 30031

English Abstract

Methods for the treatment of squamous *cell* carcinoma using a p53-expressing viral vector are disclosed. In particular embodiments, the vector is a replication-deficient adenovirus. In addition, there are provided methods for examining the development and treatment of microscopic residual disease in the context of post-surgical environments and in body cavities.

Japanese Abstract

L'invention concerne des methodes de traitement de carcinomes spino-cellulaire, dans lesquelles on utilise un vecteur viral exprimant p53. Dans des formes d'execution speciales, le vecteur est un adenovirus incapable de se multiplier. En outre, l'invention concerne des methodes permettant de suivre l'evolution et le traitement de maladies microscopiques residuelles apres une intervention chirurgicale, ainsi que dans des cavites du corps.

27/5/45 (Item 45 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00500569

IMMORTALIZED* *EPITHELIAL* TUMOR *CELL
CELLULE TUMORALE EPITHELIALE *IMMORTALISEE*

Patent Applicant/Assignee:

MICROMET GMBH

DICKMANNS Achim

FANNING Ellen

PANTEL Klaus

RIETHMULLER Gerhard

Inventor(s):

DICKMANNS Achim

FANNING Ellen

PANTEL Klaus

RIETHMULLER Gerhard

Patent and Priority Information (Country, Number, Date):

Patent: WO 9700946 A1 19970109

Application: WO 96EP2747 19960624 (PCT/WO EP9602747)

Priority Application: EP 95109860 19950623

Designated States: AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG
KP KR KZ LK LR LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR
TT UA UG US UZ LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
ES FI FR GB GR LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Main International Patent Class: C12N-005/10;
International Patent Class: C07K-016/30; A61K-039/00; A61K-039/395;
G01N-033/53;
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 9469

English Abstract

The present invention relates to *epithelial* tumor *cells* with metastatic potential which have integrated in their genome or another replicative genetic element at least one externally introduced *immortalizing* *oncogene* and optionally at least one gene encoding an immunostimulatory factor which are expressed in such tumor *cells*. The invention further relates to antibodies which specifically recognize the *epithelial* tumor *cells* of the invention, to processes for the production of said tumor *cells* as well as pharmaceutical and diagnostic compositions comprising said tumor *cells* and antibodies, respectively. Finally the present invention relates to the use of the *epithelial* tumor *cells* and/or antibodies of the invention for the preparation of tumor vaccines and medicaments for the prophylaxis and/or treatment of cancer and/or the metastasis of cancer.

Japanese Abstract

L'invention se rapporte a des cellules tumorales epitheliales ayant un potentiel metastatique qui ont integre dans leur genome ou dans un autre element genetique de repetition au moins un *oncogene* *immortalisant* introduit de facon externe et eventuellement au moins un gene codant un facteur immunostimulateur, qui sont exprimes dans de telles cellules tumorales. En outre, l'invention se rapporte a des anticorps reconnaissant specifiquement les cellules tumorales epitheliales de cette invention, a des procedes pour la production desdites cellules tumorales ainsi qu'a des compositions pharmaceutiques et de diagnostic comportant respectivement lesdites cellules tumorales et lesdits anticorps. Enfin, l'invention decrit l'utilisation des cellules tumorales epitheliales et/ou anticorps pour la preparation de vaccins antitumoraux et de medicaments pour la prophylaxie et/ou le traitement du cancer et/ou de la metastase du cancer.

27/5/46 (Item 46 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00427857 **Image available**
NEW PHARMACEUTICALS FOR MODULATING HORMONE RESPONSIVENESS
NOUVEAUX COMPOSES PHARMACEUTIQUES POUR MODULER LA CAPACITE DE REONSE AUX HORMONES

Patent Applicant/Assignee:

DEDHAR Shoukat
ST-ARNAUD Rene

Inventor(s):

DEDHAR Shoukat
ST-ARNAUD Rene

Patent and Priority Information (Country, Number, Date):

Patent: WO 9623001 A1 19960801
Application: WO 95CA664 19951123 (PCT/WO CA9500664)
Priority Application: US 95377432 19950124

Designated States: AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE
HU IS JP KE KG KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK TT UA UG US UZ VN KE LS MW SD SZ UG AT BE CH DE DK ES FR
GB GR IE IT LU PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Main International Patent Class: C07K-014/575;
International Patent Class: C07K-007/04; A61K-038/22; C12N-015/16;
Publication Language: English
Fulltext Availability:

Detailed Description
Claims
Fulltext Word Count: 20119

English Abstract

This invention relates to isolated and purified proteins, such as calreticulin and mimetics and inhibitors of calreticulin, for a novel use of modulating hormone responsiveness. These proteins are useful in gene therapy and in manufacturing pharmaceuticals for treating a variety of diseases, including cancer, osteoporosis and chronic inflammatory disease. The proteins include or bind to an amino acid sequence KXFFYR, wherein X is either G, A or V and Y is either K or R. This sequence is present in the DNA-binding domain, and is critical for the DNA binding activity, of a variety of hormone receptors, including glucocorticoid receptor, mineralocorticoid receptor, androgen receptor, progesterone receptor, estrogen receptor, retinoic acid receptor, thyroid hormone receptor and vitamin D receptor. Proteins which bind to this sequence may inhibit hormone receptor induced gene transcription. Proteins which include this sequence may promote hormone receptor induced gene transcription. The invention includes isolated DNA molecules for these proteins, methods of treating diseases using these proteins, synthetic peptides and their mimetics, and kits containing these proteins, synthetic peptides or their mimetics.

Japanese Abstract

L'invention concerne des protéines isolées et purifiées, telles que la calreticuline et les éléments mimétiques ou inhibiteur de la calreticuline, pour une utilisation nouvelle dans la modulation de la capacité de réponse aux hormones. Ces protéines sont utiles en thérapie génique et dans la fabrication de préparations pharmaceutiques servant à traiter une variété de maladies, dont le cancer, l'ostéoporose et les maladies inflammatoires chroniques. Ces protéines comprennent ou se fixent à une séquence d'acides aminés KXFFYR, dans laquelle X est G, A ou V et Y est K ou R. Cette séquence est présente dans le domaine de fixation à l'ADN et est critique pour l'activité de fixation à l'ADN d'une variété de récepteurs d'hormones, en particulier du récepteur de glucocorticoïdes, du récepteur de mineralocorticoïdes, du récepteur des androgènes, du récepteur de la progesterone, du récepteur des œstrogènes, du récepteur de l'acide retinoïque, du récepteur des hormones thyroïdiennes et du récepteur de la vitamine D. Les protéines qui se fixent à cette séquence peuvent inhiber la transcription génique induite par un récepteur d'hormone. Les protéines qui comprennent cette séquence peuvent favoriser la transcription génique induite par un récepteur d'hormone. Cette invention concerne également les molécules d'ADN isolées pour ces protéines, des procédés pour traiter des maladies à l'aide de ces protéines, des peptides synthétiques et leurs éléments mimétiques, ainsi que des kits comprenant ces protéines, ces peptides synthétiques ou leurs éléments mimétiques.

27/5/47 (Item 47 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00369843 **Image available**
MESOTHELIAL *CELL* GENE THERAPY
THERAPIE GENIQUE UTILISANT LES CELLULES MESOTHELIALES

Patent Applicant/Assignee:
BETH ISRAEL HOSPITAL ASSOCIATION

Inventor(s):

SHOCKLEY Ty Robert
JACKMAN Robert William
NAGY Janice Ann

Patent and Priority Information (Country, Number, Date):

Patent: WO 9500654 A1 19950105
Application: WO 94US6809 19940615 (PCT/WO US9406809)
Priority Application: US 9380474 19930618

Designated States: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Main International Patent Class: C12N-015/85;
International Patent Class: C12N-015/18; C12N-005/10; A61K-048/00;
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 18797

English Abstract

Methods and pharmaceutical compositions for modifying the mesothelial *cells* of a mammalian recipient in situ are provided. The methods include forming a mesothelial *cell* expression system in vivo or ex vivo and administering the expression system to the mammalian recipient (by way of the body cavities normally lined by mesothelial *cells*). The mesothelial *cell* expression system is useful for the localized and systemic delivery of therapeutic agents in situ.

Japanese Abstract

L'invention se rapporte a des procedes et a des compositions pharmaceutiques permettant la modification in situ des cellules mesotheliales d'un receveur mammifere. Ces procedes comprennent la formation d'un systeme d'expression de la cellule mesotheliale in vivo ou ex vivo et l'implantation dudit systeme au receveur mammifere (par la voie des cavites corporelles normalement tapissees de cellules mesotheliales). Le systeme permettant l'expression de la cellule mesotheliale est utile pour la liberation localisee et systemique d'agents therapeutiques in situ.

27/5/48 (Item 48 from file: 349)

DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00330864

DIAGNOSTIC AND/OR THERAPEUTIC AGENTS, TARGETED TO NEOVASCULAR ENDOTHELIAL *CELLS*
AGENTS DIAGNOSTIQUES ET/OU THERAPEUTIQUES CIBLES SUR DES CELLULES
ENDOTHELIALES NEOVASCULAIRES

Patent Applicant/Assignee:

BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
IMPERIAL CANCER RESEARCH TECHNOLOGY
THORPE Philip E
BURROWS Francis J

Inventor(s):

THORPE Philip E
BURROWS Francis J

Patent and Priority Information (Country, Number, Date):

Patent: WO 9317715 A1 19930916
Application: WO 93US1956 19930305 (PCT/WO US9301956)
Priority Application: US 92846349 19920305

Designated States: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU
MG MN MW NL NO PT RO RU SD SE SK UA US AT BE CH DE DK ES FR GB GR IE IT
LU MC NL PT SE CF CG CI CM GA GN ML MR SN TD TG

Main International Patent Class: A61K-047/48;

International Patent Class: A61K-049/00; A61K-049/02;

Publication Language: English

Fulltext Availability:

Detailed Description
Claims

Fulltext Word Count: 35038

English Abstract

The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunologically-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses

through recognition of tumor vasculature-associated antigens, or through the specific induction of endothelial *cell* surface antigens on vascular endothelial *cells* in solid tumors.

Japanese Abstract

L'invention concerne des procedes et des compositions de ciblage du systeme vasculaire de tumeurs solides au moyen de reactifs immunologiques. Dans certains modes de realisation, des anticorps porteurs d'agents diagnostiques ou therapeutiques sont cibles sur le systeme vasculaire de masses tumorales solides par reconnaissance d'antigenes associes au systeme vasculaire de tumeurs, ou par induction specifique d'antigenes de surface de cellules endotheliales sur des cellules endotheliales vasculaires dans des tumeurs solides.

27/5/49 (Item 49 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00296204

A NOVEL ONCO-FETAL GENE, GENE PRODUCT AND USES THEREFOR NOUVEAU GENE ONCO-FOETAL, PRODUIT GENETIQUE ET UTILISATIONS

Patent Applicant/Assignee:

RESEARCH DEVELOPMENT FOUNDATION

Inventor(s):

MACLEOD Carol L

Patent and Priority Information (Country, Number, Date):

Patent: WO 9206218 A1 19920416

Application: WO 91US7237 19911001 (PCT/WO US9107237)

Priority Application: US 90590894 19901001

Designated States: AT AU BE CA CH DE DK ES FI FR GB GR IT JP KR LU NL NO SE
SU

Main International Patent Class: C12Q-001/68;

International Patent Class: C07H-015/12;

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 8597

English Abstract

The present invention provides a novel cDNA sequence (Pem), a gene product protein, and uses for this novel cDNA sequence and the Pem gene product. The DNA sequence and recombinant DNA molecules of this invention are characterized in that each codes for a novel protein having the following characteristics: (1) is expressed by T-lymphoma *cells*, (2) is not expressed in normal thymus, activated spleen *cells*, gut associated lymphoid tissue, or bone marrow, and is not detectable in adult brain, liver, large intestine or ovary, (3) is expressed in *immortalized* or cancerous *cell* lines, and (4) is expressed in embryonic development.

Japanese Abstract

L'invention decrit une nouvelle sequence d'ADNc (Pem), une proteine de produit genetique, ainsi que les utilisations de cette nouvelle sequence d'ADNc et du produit genetique de Pem. La sequence d'ADN et les molecules d'ADN de recombinaison decrites par l'invention, sont caracterisees par le fait que chacune code une nouvelle proteine possedant les caracteristiques suivantes: (1) elle est exprimee par les cellules du T-lymphome, (2) elle n'est pas exprimee dans les cellules normales du thymus, les cellules activees de la rate, le tissu lymphoide associe a l'intestin ou la moelle osseuse et n'est pas detectable dans le cerveau adulte, le foie, le gros intestin et les ovaires, (3) elle est exprimee dans les lignes cellulaires *immortalisees* ou cancereuses, et, (4) elle est exprimee dans le developpement embryonnaire.

?